<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Normal B and T lymphocyte development</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Normal B and T lymphocyte development</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Normal B and T lymphocyte development</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jon C Aster, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arnold S Freedman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 29, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1229438"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Lymphocyte development involves a complex series of tightly choreographed events. The process is orchestrated by genes that act at specific stages of B or T cell differentiation that encode lineage-specific transcription factors, growth factors, and chemokines; deoxyribonucleic acid (DNA) recombinases (RAG1 and RAG2) and terminal deoxytransferase (TdT), which directs the rearrangement and diversification of B and T cell antigen receptor genes, respectively; and the DNA modifying enzyme activation-induced cytosine deaminase (AID), which is needed for immunoglobulin class-switching and somatic hypermutation, a phenomenon that is required for the production of high-affinity antibodies. </p><p>Of clinical importance, many lymphoid malignancies appear to be the neoplastic counterparts of cells "arrested" at particular stages of lymphoid differentiation, as judged by cytologic appearance, patterns of growth, immunophenotype, and genetic features. This insight serves as the organizing theme for the classification of lymphoid malignancies, which sort lymphoid tumors according to their apparent cell of origin [<a href="#rid1">1,2</a>].</p><p>This topic focuses on early events of B and T cell development and describes markers that define early and later stages of B and T cells.</p><p class="headingAnchor" id="H1229463"><span class="h1">NORMAL LYMPHOID TISSUES</span><span class="headingEndMark"> — </span>Lymphoid tissues are subdivided into primary and secondary lymphoid organs. </p><p class="bulletIndent1"><span class="glyph">●</span>The primary lymphoid tissues responsible for the initial generation of B and T lymphocytes are the bone marrow and thymus, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Secondary lymphoid tissues include lymph nodes, spleen, tonsils, and the aggregations of lymphoid tissue located in the gastrointestinal and respiratory tracts. Within these lymphoid organs, B and T lymphocytes tend to home to different domains, leading to the segregation of B and T cells. Specifically, B cells mainly localize to follicles, whereas T cells mainly localize to interfollicular areas  (<a class="graphic graphic_figure graphicRef122441" href="/d/graphic/122441.html" rel="external">figure 1</a>). Non-lymphoid cells (eg, dendritic cells, monocytes/macrophages, endothelial cells, pericytes, fibroblasts, and follicular dendritic cells) contribute to the formation of these distinct microenvironments, within which specific cell-cell interactions occur that are required for the generation of cellular and humoral immune responses [<a href="#rid3">3</a>].<strong> </strong>(See  <a class="medical medical_review" href="/d/html/3980.html" rel="external">"The adaptive cellular immune response: T cells and cytokines"</a> and  <a class="medical medical_review" href="/d/html/3975.html" rel="external">"The adaptive humoral immune response"</a>.)</p><p></p><p class="headingAnchor" id="H1229488"><span class="h1">ORIGIN OF LYMPHOID CELLS</span><span class="headingEndMark"> — </span>All white blood cells are derived from hematopoietic stem cells (HSCs). The embryonic origins of human HSCs are complex and are largely inferred from studies conducted in mice [<a href="#rid4">4</a>]. Blood forming cells first appear in the yolk sac around day 16 of gestation, but yolk sac hematopoiesis is restricted to the production of primitive red cells, platelets, and monocyte/macrophage-like progenitors that home to tissues and give rise to specialized long-lived phagocytes such as Kupffer cells in the liver and microglia in the brain [<a href="#rid5">5,6</a>]. Definitive HSCs arise in the dorsal aorta around the end of the third week of gestation. These cells bud off from "hemogenic endothelium" but are clonally distinct from aortic endothelial cells [<a href="#rid7">7-9</a>]. Work in mice has shown that lymphoid potential depends on the transcription factors Pu.1, Ikaros (Ikzf1), Bcl11a, and Tcf3 [<a href="#rid10">10</a>]. These HSCs appear to migrate to the liver, which becomes the main site of hematopoiesis after six weeks of gestation, and the placenta, which is the source of the HSCs that are found in cord blood. Progenitor cells from these tissues populate the thymus by seven to eight weeks of gestation. Bone marrow hematopoiesis commences by approximately five months of gestation and under normal circumstances is the primary source of hematopoietic cells after birth. (See  <a class="medical medical_review" href="/d/html/3536.html" rel="external">"Overview of hematopoietic stem cells"</a>.)</p><p>The earliest committed hematolymphoid progenitors are derived through asymmetric cell divisions, in which undifferentiated HSCs give rise to daughter cells with greater proliferative potential but lacking the property of self-renewal. (See  <a class="medical medical_review" href="/d/html/14598.html" rel="external">"Overview of stem cells", section on 'What defines a stem cell?'</a>.)</p><p>The events that lead to the appearance of cells that are committed to lymphoid differentiation are not completely understood. It is generally agreed that HSCs first give rise to multipotent progenitors (MPPs), a subset of which retain the capacity to produce either myeloid or lymphoid cells [<a href="#rid11">11,12</a>]. In the bone marrow, the progeny of some of these "lymphoid-competent" MPPs become committed to the B cell lineage, an event that requires the transcription factors Ebf1 and Pax5 and the suppression of Notch signaling (which otherwise overrides B cell differentiation programs and directs MPPs towards the T cell lineage). Other early progenitors in marrow (sometimes known as early thymic progenitors, or ETPs) migrate to the thymus, an organ rich in stromal cells expressing ligands that activate Notch signaling, which induces these cells to undergo T cell differentiation.</p><p class="headingAnchor" id="H1229513"><span class="h1">B CELL DEVELOPMENT</span><span class="headingEndMark"> — </span>New B cells are generated throughout life in humans [<a href="#rid13">13</a>], first in the liver during gestation and thereafter in the bone marrow. Early B cell development constitutes the steps that lead to B cell commitment and the expression of surface immunoglobulin, which is essential for B cell survival and function. These events culminate in the production of mature B cells, which leave the marrow and migrate to secondary lymphoid tissues, such as the lymph nodes, the spleen, and the Peyer's patches of the gut. Subsequent steps occur after B cells interact with exogenous antigen and/or T helper cells; these constitute the "antigen-dependent phase" that results in the generation of humoral immune responses. (See  <a class="medical medical_review" href="/d/html/3975.html" rel="external">"The adaptive humoral immune response"</a>.)</p><p>The nomenclature used to describe these steps varies somewhat among authors, and depends in part on how finely one wishes to make distinctions between "discrete" developmental stages [<a href="#rid14">14</a>]. The earliest recognizable stage is called the B progenitor cell or pre-pro-B cell. Subsequent stages include the pro-B cell; the pre-B cell; the naive or mature B cell; several different types of antigen-activated B cells; the plasma cell; and the memory B cell.</p><p>Even at the pro-B cell stage of development, lineage commitment is not complete, as these cells can be "reprogrammed" along a different pathway by combinations of cytokines and extracellular signals. As an example, progenitor B cells develop into dendritic cells when cultured with IL-1beta, IL-3, and IL-7, tumor necrosis factor, stem cell factor, and Flt-3 ligand [<a href="#rid15">15</a>]. The relevance of this finding to in vivo B cell or dendritic cell development is unclear.</p><p>As a further complication, there is evidence that the program of B cell development that occurs early in life (prenatally and during the first few post-natal years of life) differs from the program of B cell development that predominates in adults [<a href="#rid16">16</a>]. The section that follows will focus on the stepwise events of early B cell development, acknowledging that there is uncertainty about some of the details.</p><p class="headingAnchor" id="H1229574"><span class="h2">Role of immunoglobulin gene rearrangements in B cell development</span><span class="headingEndMark"> — </span>Productive rearrangement of the Ig heavy chain and light chain genes is essential for the earliest stages of B cell development and for later mature B cell maturation. The germline DNA contains segments coding for different portions of the immunoglobulin molecule. For the immunoglobulin heavy chain, these consist of roughly 40 functional variable (V) segments, 9 diversity (D) segments, 6 joining (J) segments, and a constant region for each subclass of immunoglobulin heavy chains (mu, gamma, alpha, delta, and epsilon) [<a href="#rid17">17</a>]. Light chain genes have a similar organization but lack D segments. During early stages of B cell development functional rearrangement of the heavy chain gene locus (IgH) allows for assembly of the pre-B cell receptor complex. This complex transmits signals that lead to cessation of IgH rearrangements (a process termed allelic exclusion) and initiation of light chain rearrangements, first in the kappa light chain locus and then (if these are non-productive) the lambda light chain locus. Production of a complete immunoglobulin molecule comprised of two heavy chains and two light chains allows for assembly of the mature B cell receptor on the cell surface, which transmits signals that cause the cessation of light chain gene rearrangement and further maturation to the mature B cell stage. A detailed summary of this process is discussed separately. (See  <a class="medical medical_review" href="/d/html/3977.html" rel="external">"Immunoglobulin genetics"</a>.)</p><p class="headingAnchor" id="H1229599"><span class="h2">Pro-B cells</span><span class="headingEndMark"> — </span>Extrinsic factors such as interleukin (IL)-3 and IL-7, insulin-like growth factor 1, and stem cell factor (SCF) promote the development of pro-B cells from earlier progenitors. The pro-B cell stage is denoted by the expression of Pax5, a master transcription factor that is essential for not only the generation of pro-B cells, but also all subsequent stages of B cell development up to the plasma cell stage. Other events associated with this stage are expression of RAG1 and RAG2, which catalyze D-JH rearrangements within the immunoglobulin heavy chain gene loci, and the surface expression of CD19 [<a href="#rid18">18</a>]  (<a class="graphic graphic_table graphicRef54590" href="/d/graphic/54590.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/3977.html" rel="external">"Immunoglobulin genetics"</a>.)</p><p>CD19 is a component of a multimolecular surface complex involved in signaling in response to antigen and T cell help [<a href="#rid19">19</a>]. Pro-B cells also express HLA-DR (class II histocompatibility antigen) and CD34, a 115 kD type I transmembrane glycoprotein present on other very early hematopoietic progenitors that is probably involved in cytoadhesion [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/d/html/3536.html" rel="external">"Overview of hematopoietic stem cells"</a>.)</p><p class="headingAnchor" id="H1229690"><span class="h2">Pre-B cells</span><span class="headingEndMark"> — </span>During this stage of B cell development, immunoglobulin (Ig) heavy chain genes complete V-D-J recombination, allowing the surface expression of a complex consisting of an Ig heavy chain and molecules called surrogate light chains [<a href="#rid21">21,22</a>] that show homology to Ig light chain V and C regions. (See  <a class="medical medical_review" href="/d/html/3977.html" rel="external">"Immunoglobulin genetics"</a>.)</p><p>Several of these genes have been identified in humans. VpreB is a non-rearranging gene encoding most of an Ig V domain. (See  <a class="medical medical_review" href="/d/html/3971.html" rel="external">"Structure of immunoglobulins"</a>.)</p><p>The other genes encoding surrogate light chains belong to a family called lambda 5 or lambda 5-like. The surrogate light chain genes are expressed only in pre-B cells, and the complex containing the Ig heavy chain and the surrogate light chain is called the pre-B cell receptor. Genetic defects that prevent expression of the pre-B cell receptor, or that prohibit the transduction of signals via the receptor, lead to an absence of B cells and congenital agammaglobulinemia. Loss-of-function mutations in genes that encode components of the pre-B cell receptor or downstream signaling molecules that lead to agammaglobulinemia include:</p><p class="bulletIndent1"><span class="glyph">●</span>IgM [<a href="#rid23">23</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>lambda 5 surrogate light chain [<a href="#rid24">24</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>CD79a [<a href="#rid25">25</a>] (see below)</p><p class="bulletIndent1"><span class="glyph">●</span>CD79b [<a href="#rid26">26</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Bruton tyrosine kinase (<em>BTK</em>) [<a href="#rid27">27</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>B cell linker protein (<em>BLNK</em>) [<a href="#rid28">28</a>]</p><p></p><p>These disorders are discussed separately. (See  <a class="medical medical_review" href="/d/html/3914.html" rel="external">"Primary humoral immunodeficiencies: An overview"</a>.)</p><p>The requirement of BTK for the survival of mature B cells led to development of BTK inhibitors, such as <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a>, which are widely used in the treatment of B cell malignancies. (See  <a class="medical medical_review" href="/d/html/4520.html" rel="external">"Treatment of relapsed or refractory chronic lymphocytic leukemia", section on 'Ibrutinib'</a> and  <a class="medical medical_review" href="/d/html/4735.html" rel="external">"Treatment of relapsed or refractory mantle cell lymphoma", section on 'Bruton tyrosine kinase inhibitors'</a>.)</p><p>ZAP-70, a 70-kDa Syk-family protein tyrosine kinase that is also expressed on T cells and natural killer cells, may also be required for pre-B cell receptor signaling, based on defects observed in ZAP-70 deficient mice [<a href="#rid29">29</a>].</p><p>The assembled pre-B cell receptor transmits pro-growth signals that result in a 32- to 64-fold expansion (five or six cell divisions) in cell numbers. It is not clear whether pre-B cell signaling is autonomous or follows receptor activation by a currently unknown ligand.</p><p>A number of markers first appear during the pre-B cell stage.</p><p class="bulletIndent1"><span class="glyph">●</span>CD79a and CD79b (Ig-alpha and Ig-beta, respectively), which associate non-covalently with surface Ig and constitute the signal transducing components of the pre-B cell receptor. Ig-alpha and Ig-beta are also components of the Ig receptors on the surface of mature B cells.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CD10 (also known as common acute lymphoblastic leukemia antigen [CALLA], neutral endopeptidase 24.11, or enkephalinase [<a href="#rid30">30-33</a>]) is a zinc metalloprotease capable of inactivating a variety of peptide hormones including glucagon, enkephalin, atrial natriuretic peptide, substance P, oxytocin, bradykinin, neurotensin and angiotensins I and II, as well as f-Met-Leu-Phe.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CD20 is a tetraspan phosphoprotein that resides in lipid raft domains [<a href="#rid34">34</a>]. CD20 functions as a Ca<sup>++ </sup>conductive ion channel that may regulate B cell activation and cell cycle progression [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CD29/49d is a member of the beta-1 integrin family of cell adhesion molecules [<a href="#rid36">36</a>]. It is involved in the adhesion of pre-B cells to bone marrow stromal cells via its ligands VCAM-1 and the extracellular matrix protein fibronectin [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CD40, a member of the TNF receptor family, is a 50 kD phosphoprotein expressed on a subset of pre-B cells. CD40 is involved in growth regulation of B cells and immunoglobulin class switching [<a href="#rid38">38</a>]. CD154, the ligand for CD40, is expressed on activated CD4+ T cells and is a member of the tumor necrosis alpha family [<a href="#rid39">39</a>]. The CD40-CD154 interaction is central to the generation of humoral responses to T-cell dependent antigens. (See  <a class="medical medical_review" href="/d/html/3975.html" rel="external">"The adaptive humoral immune response"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CD22 is a member of the Ig superfamily that binds to sialic acid-bearing molecules on other hematopoietic and non-hematopoietic cells. CD22 down-regulates signaling by antigen receptors by recruiting antagonistic signaling molecules, including the tyrosine phosphatase SHP-1 [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>TdT (terminal deoxytransferase) is a specialized DNA polymerase that adds random nucleotides to double-stranded DNA breaks created by RAG1 and RAG2, thereby contributing to the diversification of Ig genes. TdT is a sensitive marker for benign and malignant pre-B cells, but is not specific, as benign and malignant pre-T cells also express TdT.</p><p></p><p class="headingAnchor" id="H1230059"><span class="h2">Immature B cells</span><span class="headingEndMark"> — </span>Transition from the pre-B cell stage to the immature B cell stage is marked by successful rearrangement of either a kappa or lambda Ig light chain gene, which permits the expression of a complete IgM antibody molecule on the cell surface. If surface IgM interacts strongly with membrane-bound self-antigen (such as MHC) on other cells, then that B cell either dies by apoptosis or undergoes further Ig gene rearrangement (a process called receptor editing) to create a new Ig with a different specificity (see  <a class="medical medical_review" href="/d/html/3977.html" rel="external">"Immunoglobulin genetics"</a>). Immature B cells continue to express HLA-DR, CD19, CD20, and CD40, but no longer express CD10, CD34, RAG1, RAG2, or TdT.</p><p>Rearrangement of kappa light chain genes generates a by-product called a "kappa recombination excision circle" (KREC) [<a href="#rid41">41</a>]. This is an episomal circular DNA fragment derived from the DNA that lies between the Vkappa and Jkappa gene segments prior to rearrangement (see  <a class="medical medical_review" href="/d/html/3977.html" rel="external">"Immunoglobulin genetics", section on 'Immunoglobulin gene organization'</a>). KRECs are not replicated but are carried in the nucleus of one of the daughter cells arising from a round of B cell division. As a result, KRECs are readily detectable in the peripheral blood of healthy individuals, and an abnormally low level of KRECs indicates some process that impedes B cell development. KREC measurement is undergoing development as a potential screening tool for defective B cell development in newborns or older individuals. (See  <a class="medical medical_review" href="/d/html/16363.html" rel="external">"Newborn screening for inborn errors of immunity", section on 'Screening for B cell defects'</a>.)</p><p class="headingAnchor" id="H3045085262"><span class="h2">Mature B cells</span><span class="headingEndMark"> — </span>After exiting the bone marrow, immature B cells migrate to secondary lymphoid organs, principally the spleen and lymph nodes. Cells in the spleen represent an intermediate stage of B cell development and are called "transitional B cells." Within the splenic white pulp, these cells can further differentiate in follicular B cells or splenic marginal zone B cells, a fate choice that is influenced by Notch signaling, which enforces marginal zone fate at the expense of follicular fate [<a href="#rid42">42</a>]. Splenic marginal zone B cells appear to differentiate into short-lived plasma cells that make polyreactive antibodies that protect against certain bacterial infections [<a href="#rid43">43</a>]. </p><p>Other B cells migrate to other secondary lymphoid organs, principally the lymph nodes, tonsils, spleen, Peyer's patches, and less well-organized collections of lymphocytes that are found in the respiratory tract, gastrointestinal tract, and the skin. These B cells enter tissue by binding to a specialized endothelium within small vessels known as high endothelial venules [<a href="#rid44">44</a>]. Two surface molecules, CD44 [<a href="#rid45">45-48</a>] and CD62-L (L-selectin) [<a href="#rid49">49-52</a>], play important roles in lymphocyte extravasation. Once within organized secondary lymphoid tissues, mature B cells express both surface IgM and IgD, and well as other molecules that mediate cell-cell and cell-extracellular matrix adhesive interactions, including CD11a/CD18 (LFA-1) and CD29/49d (VLA-4) [<a href="#rid53">53,54</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Surface immunoglobulin (sIg) mediates antigen binding and internalization for antigen presentation and is also linked to signal transduction pathways that are triggered by receptor aggregation. The receptor complex consists of a transmembrane form of a complete Ig molecule and two heterodimers comprised of Ig-alpha (CD79a) and Ig-beta (CD79b) [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/d/html/3971.html" rel="external">"Structure of immunoglobulins"</a>.)</p><p></p><p class="bulletIndent1">The cytoplasmic portions of Ig-alpha and beta proteins contain short sequences called "immunoreceptor tyrosine-based activation motifs" (ITAMs). Similar sequences are found in the cytoplasmic portions of molecules constituting the T cell antigen receptor complex and the high affinity IgE Fc receptor. These motifs participate in protein-protein interactions that link Ig-alpha and Ig-beta to signaling pathways in the cytoplasm [<a href="#rid18">18</a>]. As mentioned above, Ig-alpha and Ig-beta are also required for pre-B cell receptor signaling in pre-B cells, and mutations in Ig-alpha or Ig-beta in humans are associated with a lack of B cell development and agammaglobulinemia [<a href="#rid25">25</a>]. (See <a class="local">'Pre-B cells'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CD11a (integrin alpha-L) is non-covalently associated with CD18 (integrin beta-2) [<a href="#rid50">50</a>]. Within secondary lymphoid tissues, CD11a/CD18 mediates B cell binding to B cells, T cells, monocytes, and follicular dendritic cells via its ligand ICAM-1 (CD54). (See  <a class="medical medical_review" href="/d/html/3983.html" rel="external">"Leukocyte-endothelial adhesion in the pathogenesis of inflammation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CD20 is present on more than 95 percent of B cells in both peripheral blood and in secondary lymphoid organs. As mentioned previously, this molecule may function as a membrane ion channel that plays a role in B cell activation. Loss-of-function mutations in CD20 are associated with defects in T cell independent B cell responses to antigen [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CD19 and CD20 are the markers most often used to enumerate B cells in routine clinical applications of flow cytometry [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In addition, the anti-CD20 antibody, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, is a widely used therapy for several malignant and autoimmune diseases; this antibody kills B cells, both by fixing complement and initiating antibody-dependent cell-mediated cytotoxicity, and its use leads to a transient reduction in B cell numbers and hypogammaglobulinemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CD19 and CD21 are present on the B cell membrane in a complex with CD81 (TAPA-1) and interferon induced transmembrane protein 1 (IFITM1, also known as CD225) [<a href="#rid19">19</a>]. This complex has an important role in lowering the signaling threshold of the Ig receptor complex. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CD21 is also the receptor for the C3d complement fragment and for the Epstein-Barr virus (EBV). CD21 (also known as CR2) is found on the majority of resident B cells within secondary lymphoid tissues but is infrequently expressed on B cells in the peripheral blood. Signaling via CD21 is important in B cell activation, in the development of B cell memory, and in regulating the production of autoantibodies [<a href="#rid57">57</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>EBV can infect B cells via CD21, and this property has been exploited to transform cultured peripheral blood mononuclear cells into cell lines that will grow indefinitely, providing useful tools to study a variety of aspects of B cell biology and other genetic disorders. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In addition to CD21, B cells also express CD35, which is the C3b complement receptor 1. B cells can utilize these complement receptors to bind immune complexes, an event that can lead to B cell activation. (See  <a class="medical medical_review" href="/d/html/3967.html" rel="external">"Regulators and receptors of the complement system"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CD29 (integrin beta-1) associates with CD49d (integrin alpha-4) to form VLA-4, which mediates adhesion of activated B cells to follicular dendritic cells in germinal centers through binding to its ligand VCAM-1 (CD106) [<a href="#rid58">58</a>]. Follicular dendritic cells in turn stimulate B cell growth [<a href="#rid59">59</a>] and modulate the levels of factors that regulate germinal center B cell migration [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CD40 is a receptor for CD154 (CD40 ligand), which is expressed on activated T cells. CD40 plays a central role in antigen-dependent B cell development in lymphoid tissues [<a href="#rid61">61</a>]. (See  <a class="medical medical_review" href="/d/html/3975.html" rel="external">"The adaptive humoral immune response"</a>.)</p><p></p><p>Mature B cells express many other surface molecules as well, some of which are restricted to the B cell lineage  (<a class="graphic graphic_table graphicRef78500 graphicRef57546" href="/d/graphic/78500.html" rel="external">table 2A-B</a>). This table also shows the temporal sequence of the expression of some of the markers used to follow B cell development.</p><p class="headingAnchor" id="H1230519"><span class="h2">B cell subsets</span><span class="headingEndMark"> — </span>All mature B cells have immunoglobulin receptors and express CD19 and CD20, but can be divided into subgroups based on expression of other surface markers  (<a class="graphic graphic_table graphicRef68762" href="/d/graphic/68762.html" rel="external">table 3</a>). These subsets are functionally distinct and may have different roles in the immune system. There is some evidence that these subsets diverge prior to immunoglobulin gene rearrangement at very early stages of B cell development.</p><p>B cells have been classified into two major types:</p><p class="bulletIndent1"><span class="glyph">●</span>CD5- (or "conventional" B cells, also called B-2 cells)</p><p class="bulletIndent1"><span class="glyph">●</span>CD5+ (also called B-1 cells, which are further subdivided into B-1a and B-1b)</p><p></p><p>CD5 is expressed by T cells and some B cells. A ligand for CD5 on human B cells is CD72, a cell surface molecule of unknown function that is also expressed on B cells [<a href="#rid62">62</a>]. The functions of CD5 and CD72 on B cells are not known. There are data from mice suggesting that CD5 acts to suppress signaling via the Ig receptor [<a href="#rid63">63</a>].</p><p>Each of these B cell populations is distinct with respect to its immunophenotype, requirements for activation, and responses to ligation of certain receptors. However, B-1b cells have some characteristics in common with both B-1a and B-2 cells  (<a class="graphic graphic_table graphicRef68762" href="/d/graphic/68762.html" rel="external">table 3</a>) [<a href="#rid64">64</a>].</p><p>The CD5+ (B-1a) subset is prominent early in ontogeny, as CD5 is expressed on the following cells:</p><p class="bulletIndent1"><span class="glyph">●</span>Almost all fetal liver B cells</p><p class="bulletIndent1"><span class="glyph">●</span>40 to 60 percent of fetal spleen B cells</p><p class="bulletIndent1"><span class="glyph">●</span>60 to 80 percent of umbilical cord blood B cells</p><p></p><p>In adults, 5 to 30 percent of B cells in the peripheral blood are B-1a cells, 4 to 6 percent are B1-b cells, and 65 to 89 percent are B-2 cells. CD5+ B cells are also prominent in the peritoneal cavity (19 to 76 percent), and can be found in the lymph nodes and in the spleen [<a href="#rid65">65-68</a>].</p><p>B-1a cells appear to be a self-renewing population of cells that is primed to produce polyreactive low affinity antibodies ("natural antibody") that interact with a wide variety of foreign and self-antigens. These include IgG Fc, single-stranded DNA, thyroglobulin, insulin, E. coli beta-galactosidase, and tetanus toxoid [<a href="#rid69">69</a>]. These self-reactive antibodies are mainly encoded by rearranged immunoglobulin genes that carry few, if any, somatic mutations, consistent with the view that B-1a cells fail to pass through germinal centers and do not experience a germinal center reaction (see  <a class="medical medical_review" href="/d/html/3977.html" rel="external">"Immunoglobulin genetics"</a>). Most B-1a cells produce IgM antibodies. Despite having some self-reactivity, these antibodies occur in healthy individuals and are not themselves pathogenic. They may have a beneficial role in host defense through their IgG-binding (rheumatoid factor) activity, which could enhance immune complex formation, complement lysis, or opsonization and phagocytosis [<a href="#rid69">69-71</a>]. These antibodies may also assist in homeostasis by binding to aging and apoptotic cells and cellular debris, which if not cleared, might be proinflammatory and immunogenic [<a href="#rid72">72</a>].</p><p>It has also been suggested that CD5+ B cells have a relatively greater role in the primary immune response to antigen [<a href="#rid73">73</a>]. This stems from their capacity to rapidly differentiate into antibody-secreting plasma cells following activation (described below), thus providing some measure of humoral immunity during the week or so lag between initial exposure to antigen and the appearance of specific high-affinity antibodies [<a href="#rid70">70</a>].</p><p>Mature B cells circulate as resting cells for days or weeks, but if they are not activated within that period of time, they die by apoptosis and are replaced by new B cells. The antigen-dependent phase of B cell development is synonymous with the generation of the humoral immune response. (See  <a class="medical medical_review" href="/d/html/3975.html" rel="external">"The adaptive humoral immune response"</a>.)</p><p>In addition to these two B cell subsets, there is a small population of circulating regulatory B cells (Bregs), which secrete IL-10 and suppress T cell function [<a href="#rid74">74</a>]. These cells are enriched within a B cell population that expresses CD24 and CD1d and appear to contribute to immune tolerance by inhibiting Th1 responses, inhibiting Th17 differentiation, and favoring Treg differentiation [<a href="#rid75">75,76</a>]. Breg dysfunction may be linked to disorders of altered immunity, including autoimmune disease, allergy, infection, and cancer, all of which are active areas of investigation.</p><p class="headingAnchor" id="H1230750"><span class="h2">B cell activation</span><span class="headingEndMark"> — </span>Exposure to antigen or various polyclonal mitogens activates resting B cells and stimulates their proliferation. Activated B cells lose expression of sIgD and CD21, and acquire expression of other proteins termed activation antigens, which fall into several classes:</p><p class="bulletIndent1"><span class="glyph">●</span>Growth factor receptors</p><p class="bulletIndent1"><span class="glyph">●</span>Structures involved in cell-cell interaction</p><p class="bulletIndent1"><span class="glyph">●</span>Molecules that play a role in the localization and binding of activated B cells within various microenvironments</p><p></p><p>Specific activation antigens include the following proteins [<a href="#rid77">77</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>CD23, a 45 kD glycoprotein, is the low affinity receptor for IgE; a soluble form is reported to have B cell growth promoting activity [<a href="#rid78">78</a>] (see  <a class="medical medical_review" href="/d/html/5542.html" rel="external">"The biology of IgE"</a>). Monoclonal antibodies against CD23 inhibit IgE production [<a href="#rid79">79</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CD25, the 55 kD Tac Ag, is the alpha chain of the IL-2 receptor (high affinity); it is present on activated B cells, T cells and monocytes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CD27 (also called TNF receptor superfamily member 7 or TNFRSF7) is a ligand for CD70 (TNFSF7); these are markers of both B cell and T cell activation. Surface CD27 is often used as a marker for the enumeration of memory versus naïve B cells. (See <a class="local">'Memory B cells'</a> below and  <a class="medical medical_review" href="/d/html/3904.html" rel="external">"Pathogenesis of common variable immunodeficiency"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CD71, the transferrin receptor, which is expressed on all proliferating cells.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CD80 and CD86 are glycoprotein members of the Ig gene superfamily [<a href="#rid80">80</a>]. These molecules are ligands for the T cell antigen CD28 and provide a costimulatory signal that is critical for optimal T cell activation and proliferation following presentation of antigen in the context of MHC to the T cell receptor (see  <a class="medical medical_review" href="/d/html/3969.html" rel="external">"Major histocompatibility complex (MHC) structure and function"</a>). This signal leads to augmented cytokine secretion, including IL-2, which optimizes T cell help to B cells (see  <a class="medical medical_review" href="/d/html/3975.html" rel="external">"The adaptive humoral immune response"</a>). Subsequent to CD28 expression, T cells express CTLA-4, which interacts with CD80 and CD86 to turn off the T cell response.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Following activation, B cells also express Fas (CD95), another member of the tumor necrosis factor (TNF) receptor family. Binding of Fas to its natural ligand (Fas ligand, FasL, CD95L), which is expressed on activated T cells, triggers apoptotic cell death. Thus, Fas regulates clonal expansion of autoreactive B cells. Fas is present on germinal center B cells and B cells in sinusoids of lymphoid tissues but is expressed at much lower levels on precursor B cells, mature sIgD+ naive B cells, and plasma cells. (See  <a class="medical medical_review" href="/d/html/5594.html" rel="external">"Apoptosis and autoimmune disease"</a>.)</p><p></p><p class="headingAnchor" id="H1230945"><span class="h2">Maturation of activated B cells</span><span class="headingEndMark"> — </span>The paths that B cells follow after activation varies depending on whether they concomitantly receive co-signals from antigen-activated T cells. B-1b and B-2 cells are preferentially activated by T cells. T cell-activated B cells migrate under the influence of chemokines to the mantle zone of germinal centers where they acquire CD5 expression transiently, and then enter the germinal center.</p><p>Activated germinal center B cells are large rapidly dividing cells that express activation-induced cytosine deaminase (AID) and uracil nucleoside glycosylase (UNG), DNA modifying enzymes that mediate somatic mutation of the Ig genes (somatic hypermutation). However, AID is error-prone and germinal center B cells have a higher than normal mutation rate involving other genomic loci as well [<a href="#rid81">81</a>]. One gene that is often mutated at a high rate in normal germinal center B cells encodes the transcription factor Bcl-6 [<a href="#rid81">81</a>], a master regulator that is required for the formation of B cell follicles. Follicular B cells re-express CD10 and also turn on expression of several other antigens, such as GCET1, which has been used to sub-classify tumors of follicular B cell origin [<a href="#rid82">82</a>].</p><p>Most follicular B cells die, but a few that express antibodies that recognize antigen with high affinity receive survival signals through the Ig receptor. These cells next undergo Ig class switching, an event also requiring AID that permits B cells to express Ig molecules other than IgM. Class switching is influenced by cytokines; for example, in the presence of high levels of TGF-beta, B cells preferentially switch to IgA heavy chain [<a href="#rid83">83</a>]. The hyper-IgM syndromes are rare human immunodeficiency states characterized by a failure of Ig class switching and a marked hyperplasia of germinal center B cells (see  <a class="medical medical_review" href="/d/html/13567.html" rel="external">"Hyperimmunoglobulin M syndromes"</a>). They are caused by loss-of-function mutations in AID, UNG, CD40, or CD40L [<a href="#rid84">84</a>]. Following class switching, B cells leave the germinal center and either undergo terminal differentiation into plasma cells or enter into the long-lived memory B cell pool.</p><p>In the absence of T cell help, most activated B cells rapidly mature into short-lived plasma cells without undergoing somatic hypermutation or class switching; as a result, these cells secrete IgM antibodies of low affinity. B-1 B cells may preferentially follow this "non-follicular" differentiation pathway, as they appear to be much less dependent on T cell help for antibody production [<a href="#rid64">64</a>]. A subset of memory B cells can develop without interactions with T cells [<a href="#rid85">85</a>]. These T-independent memory B cells provide protection from microbes expressing thymus-independent antigens (eg, pneumococcal capsular polysaccharides), but these memory cells persist only for several years, whereas T-dependent memory B cells (eg, measles antibody) may persist for decades.</p><p class="headingAnchor" id="H1231030"><span class="h2">Plasma cells</span><span class="headingEndMark"> — </span>The plasma cell is large, up to 20 microns in diameter, and secretes antibodies prodigiously, although it has few antibody molecules on its surface [<a href="#rid86">86</a>]. Plasma cells that arise from follicular B cells are found mainly in the bone marrow and are long-lived (months to years), whereas plasma cells arising from non-follicular B cells have life spans of only days to a few weeks. Plasma cell differentiation is accompanied by the loss of Bcl-6, Pax-5, CD19, CD20, and B cell activation antigens, and the appearance of the transcription factors X-box binding protein 1 (XBP-1) and PR domain-containing protein 1 (PRDM1, also called B-lymphocyte-induced maturation protein 1 [BLIMP-1] and positive regulatory domain I-binding factor [PRDIBF1]); cytoplasmic Ig (cIg); and the antigens CD38 and syndecan-1 (CD138) [<a href="#rid87">87-89</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>CD38 is a cell surface glycoprotein that also is present on thymocytes, immature myeloid cells, and subsets of hematopoietic stem cells. CD38 is ADP-ribosyl cyclase whose substrate is nicotinamide adenine dinucleotide (NAD). In addition to its enzymatic function, CD38 is involved in Ca<sup>++</sup> mobilization, signal transduction, and adhesion [<a href="#rid90">90</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CD138, also called syndecan-1, is a heparan sulfate proteoglycan that acts as an adhesion molecule; it serves as a useful diagnostic marker for plasma cells [<a href="#rid91">91</a>].</p><p></p><p class="headingAnchor" id="H1231087"><span class="h2">Memory B cells</span><span class="headingEndMark"> — </span>The memory B cell is identical in appearance to resting mature B cells. The factors that influence a B cell to become a memory cell rather than a plasma cell are incompletely understood; mouse models suggest that CD40 signaling, cytokines such as IL-21, and signals transmitted by interactions with T follicular helper cells (Tfh cells) all have a role [<a href="#rid85">85</a>]. Memory cells are more sensitive to antigen stimulation and proliferate and generate plasma cells more rapidly than do mature B cells. These plasma cells are responsible for the rapid appearance of high affinity antibodies in secondary immune responses. The life span of the memory cell is not precisely known, but they may persist for years, if not decades [<a href="#rid92">92</a>]. (See  <a class="medical medical_review" href="/d/html/3975.html" rel="external">"The adaptive humoral immune response"</a>.)</p><p>Recall that mature naïve B cells express surface IgM and IgD. After activation, B cells no longer express IgD. If a memory B cell underwent class-switching in a germinal center it will express either IgG, IgA, or IgE on its surface; if not, it will retain expression of IgM and IgD ("unswitched"). Memory B cells also express CD27 (see <a class="local">'B cell activation'</a> above). This interaction modulates memory B cell activation. (See  <a class="medical medical_review" href="/d/html/3975.html" rel="external">"The adaptive humoral immune response"</a>.)</p><p>Using these markers, one may distinguish several subsets of B cells:</p><p class="bulletIndent1"><span class="glyph">●</span>Mature naïve B cells – IgM+IgD+CD27-</p><p class="bulletIndent1"><span class="glyph">●</span>Unswitched memory B cells – IgM+IgD+CD27+</p><p class="bulletIndent1"><span class="glyph">●</span>Switched memory B cells – IgM-IgD-CD27+</p><p></p><p>Alterations in these subsets may have significant clinical associations in some forms of humoral immunodeficiency [<a href="#rid93">93,94</a>]. (See  <a class="medical medical_review" href="/d/html/3904.html" rel="external">"Pathogenesis of common variable immunodeficiency"</a>.)</p><p>More information on antigen-dependent B cell development is available elsewhere. (See  <a class="medical medical_review" href="/d/html/3975.html" rel="external">"The adaptive humoral immune response"</a>.)</p><p class="headingAnchor" id="H65619706"><span class="h1">T LYMPHOCYTES</span></p><p class="headingAnchor" id="H1357858535"><span class="h2">T cell development</span></p><p class="headingAnchor" id="H1231171"><span class="h3">T cell lineages</span><span class="headingEndMark"> — </span>The majority (usually &gt;95 percent) of circulating T cells express the T cell receptor (TCR; CD3) containing chains designated alpha and beta (TCR alpha/beta, also called TCR2). The remainder of cells express receptors that include the homologous gamma and delta chains (TCR gamma/delta, or TCR1)  (<a class="graphic graphic_figure graphicRef75287" href="/d/graphic/75287.html" rel="external">figure 2</a>). CD3 is the marker most widely used to identify total T cells on routine flow cytometry, including CD4 and CD8 cells.</p><p>Most T cells develop in the thymus, while a distinct population develops in the intestinal lamina propria. An overall scheme of thymic T cell development, based on work performed in the mouse, is shown in the figure  (<a class="graphic graphic_figure graphicRef76102" href="/d/graphic/76102.html" rel="external">figure 3</a>). The details of extrathymic T cell development and the relationship of extrathymic T cells to their more numerous thymus-derived counterparts are still obscure. T cell development is more completely understood in the mouse due to its widespread use in experimental immunologic studies, but a very similar set of events is believed to occur during the intrathymic development of human T cells.</p><p>Gamma-delta and alpha-beta T cell development diverge at early stages of intrathymic development, and mature alpha-beta and gamma-delta T cells differ in their tissue distribution, mechanisms of antigen recognition, requirements for activation, and roles in immune responses. (See  <a class="medical medical_review" href="/d/html/3980.html" rel="external">"The adaptive cellular immune response: T cells and cytokines"</a>.)</p><p><em>TCR</em> genetics; discussion of the alpha, beta, gamma, and delta genes; and cellular interactions in T cell activation and effector mechanisms are discussed separately. (See  <a class="medical medical_review" href="/d/html/3950.html" rel="external">"T-B-NK+ SCID: Pathogenesis, clinical manifestations, and diagnosis", section on 'T cell receptor generation'</a>.)</p><p class="headingAnchor" id="H1231244"><span class="h3">T cell development</span><span class="headingEndMark"> — </span>During human fetal development, lymphoid progenitor cells capable of becoming T cells initially appear in the liver by approximately six weeks of gestation, and then shift by approximately five months of gestation to the bone marrow, which is the major source of T cell progenitors throughout the remainder of life. T lymphoid priming of marrow progenitors may require exposure to marrow stromal cells that express the Notch ligand DLL4; if so, such interactions must be transient or weak to avoid ectopic T cell development in the marrow [<a href="#rid95">95</a>] Progenitor cells reach the thymus via the blood, entering into the thymus through venules near the corticomedullary junction and then migrating to the outer cortex. In humans, T cell progenitors are detected in the thymus by nine weeks of gestation, and mature T cells appear in the peripheral lymphoid organs by 24 weeks of gestation [<a href="#rid96">96</a>].</p><p>As a result of robust T cell development in utero, humans (unlike mice) are born with a full complement of T cells, including T effector cells and regulatory T cells [<a href="#rid97">97</a>]. This distinction may explain the observation that neonatal thymectomy in humans (eg, during cardiac surgery) causes only subtle defects in T cell function well into adult life. Imaging studies also suggest that partial regeneration of the thymus is common in thymectomized individuals [<a href="#rid98">98</a>], which may also mitigate the deleterious effects of thymectomy. Thymopoiesis in humans begins to decline early in life, particularly after puberty, and is minimal in most individuals &gt;40 years of age, as assessed by studies of organ donors and by measuring markers of T cell production in the peripheral blood. The latter include CD31, a marker found on new thymic emigrants [<a href="#rid99">99</a>], and quantification of T cell receptor excision circles (TRECs; described below). (See <a class="local">'The mature phase'</a> below.)</p><p>Certain cell-surface molecules serve as markers of T cell differentiation  (<a class="graphic graphic_figure graphicRef76102" href="/d/graphic/76102.html" rel="external">figure 3</a>). The marker that is expressed earliest in bone marrow progenitors is CD7. As with very early B cell progenitors, early cells expressing CD7 are not yet committed to the T cell lineage. The role of CD7 in T cell differentiation is unknown. It may be a ligand for a complex family of glycoproteins called galectins, whose physiologic functions are still unclear [<a href="#rid100">100</a>]. Some CD7+ cells also express CD34, a marker of hematopoietic stem cells and early T, B, and myeloid cell progenitors [<a href="#rid101">101</a>].</p><p class="headingAnchor" id="H1231299"><span class="h3">Intrathymic regulatory factors</span><span class="headingEndMark"> — </span>A variety of highly specialized types of epithelial cells play critical roles in thymic T cell development. They are classified based upon location within the thymus, physical appearance, surface staining characteristics, and secreted products  (<a class="graphic graphic_table graphicRef77368" href="/d/graphic/77368.html" rel="external">table 4</a>) [<a href="#rid102">102,103</a>]. The biology of these cells is still poorly understood, although common progenitors have been identified in mice. If the same is true in humans, it may be possible to use these cells in thymic culture systems to create therapeutic T cells from undifferentiated progenitors [<a href="#rid104">104,105</a>].</p><p>Like B cell development, T cell development depends on intrinsic functions provided by transcription factors and extrinsic signals provided by soluble factors and cell-cell interactions. Transcription factors required at very early stages of T cell development include GATA-3, TCF-1, and Bcl11b. Of these factors, TCF-1 appears to be particularly important in establishing chromatin states that are permissive for T cell potential and for induction of differentiation by Notch signaling [<a href="#rid106">106</a>]. Interactions between thymic epithelial cells (TEC) and developing T cells (thymocytes) are mediated by specific membrane ligands, and by secreted factors (a broad array of cytokines and neuropeptides). Among the most important ligands are DLL4 and Jagged2, which activate the Notch1 receptor on early T cell progenitors. In the absence of Notch signals, commitment of early progenitors to T cell fate fails to occur [<a href="#rid107">107</a>]. Conversely, constitutive activation of Notch1 in the bone marrow compartment leads to a failure of B cell development and ectopic T cell development. The cytokine interleukin-7 (IL-7) is also produced by thymic epithelial cells and contributes to the proliferative burst that occurs early in intrathymic T cell development  (<a class="graphic graphic_figure graphicRef76102" href="/d/graphic/76102.html" rel="external">figure 3</a>) [<a href="#rid108">108</a>]. In fact, both B and T cell development is completely blocked in the absence of functional IL-7 receptor, which leads to a form of severe combined immunodeficiency [<a href="#rid109">109</a>]. TECs and thymocytes also respond to endocrine and neural signals [<a href="#rid110">110</a>]. Thymic development depends upon intact pituitary and thyroid function, while overproduction of gonadal or adrenal steroids may lead to thymic involution due to the steroid sensitivity of developing T cells.</p><p>Thymic epithelial cells also produce a variety of thymus-specific hormones and cytokines required for T cell differentiation.</p><p class="bulletIndent1"><span class="glyph">●</span>Thymopoietin (TP) refers to three protein isoforms generated by differential mRNA splicing of transcripts expressed from a single gene [<a href="#rid111">111</a>]. TP promotes T cell development, inhibits B cell development, interacts with acetylcholine receptors, and stimulates release of adrenocorticotropic hormone and beta-endorphin by the pituitary gland.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thymosins are a group of low molecular weight (3-4 kD) proteins that also promote thymic T cell differentiation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thymulin is a zinc-binding nonapeptide that potentiates signaling through the IL-2 receptor, and promotes development of IL-2 receptor-positive thymocytes [<a href="#rid103">103</a>].</p><p></p><p>The roles of all of these molecules in T lymphocyte differentiation still require clarification.</p><p class="headingAnchor" id="H1231468"><span class="h3">Intrathymic T cell development</span><span class="headingEndMark"> — </span>A general scheme of T cell development in the thymus is shown in the figure  (<a class="graphic graphic_figure graphicRef76102" href="/d/graphic/76102.html" rel="external">figure 3</a>). Once early T cell progenitors take up position in the outer cortex, they enlarge and begin to proliferate rapidly. These immature precursors represent only 2 to 3 percent of the total number of cells within the thymus [<a href="#rid112">112</a>]. After the proliferative phase, cells take on the appearance of small resting lymphocytes, and migrate through the cortex toward the medulla. In addition to Notch and IL-7, a broad array of additional cytokines and chemokines as well as adhesion molecules and components of the extracellular matrix act in concert to guide thymocyte development and migration through the thymus, a complex process that is still being unraveled [<a href="#rid113">113</a>]. Importantly, approximately 95 percent of cortical cells die as a result of selective processes (see below) before they reach the medulla.</p><p>Thymocytes at different stages of development can be identified by the expression of various surface molecules. As mentioned above, the most immature thymocytes are CD7+. In addition to these markers  (<a class="graphic graphic_figure graphicRef76102" href="/d/graphic/76102.html" rel="external">figure 3</a>), early T cell precursors express CD2, an adhesion molecule important in intercellular contacts between T cells and other cells participating in immune responses. As thymocytes mature further they begin to express CD1, a molecule homologous to MHC class I, which may interact with glycolipid antigens and present them to gamma-delta T cells [<a href="#rid114">114</a>]; its role in T cell development is unknown.</p><p>In the early stages of development, thymocytes are called double negative (DN) since they express CD3 but neither CD4 nor CD8. During this time, gamma/delta and beta chain gene rearrangement is occurring (see  <a class="medical medical_review" href="/d/html/3950.html" rel="external">"T-B-NK+ SCID: Pathogenesis, clinical manifestations, and diagnosis", section on 'T cell receptor generation'</a>). There are four DN stages (DN1-DN4) distinguished by expression of CD44 and CD25 [<a href="#rid112">112</a>]  (<a class="graphic graphic_figure graphicRef76102" href="/d/graphic/76102.html" rel="external">figure 3</a>).</p><p>CD44 is a hyaluronan receptor and ligand for E-selectin [<a href="#rid115">115</a>], while CD25 is the alpha chain of the receptor for IL-2 (IL-2R) [<a href="#rid116">116</a>]. The DN3 stage is a critical developmental checkpoint during alpha/beta T cell development. At this stage the cells express the RAG1/RAG2 DNA recombinase and rearrange their TCR beta genes (see  <a class="medical medical_review" href="/d/html/3950.html" rel="external">"T-B-NK+ SCID: Pathogenesis, clinical manifestations, and diagnosis", section on 'T cell receptor generation'</a> and  <a class="medical medical_review" href="/d/html/3977.html" rel="external">"Immunoglobulin genetics"</a>). Cells with productive rearrangements express TCR beta chains in complex with pre-TCR-alpha, a pseudo-alpha chain that functions much like surrogate light chains during pre-B cell development  (<a class="graphic graphic_figure graphicRef75287" href="/d/graphic/75287.html" rel="external">figure 2</a>). The pre-TCR complex associates with the CD3 complex and transmits signals that drive proliferation and promote cell survival [<a href="#rid112">112,113</a>]. Cells that fail to successfully rearrange their TCR-beta genes arrest and die at the DN3 stage. There are also data to suggest that the presence of an invariant chain of CD3, the delta chain, is essential for T cell development [<a href="#rid117">117</a>].</p><p>Signaling via the pre-TCR triggers the expression of CD4 and CD8 (ie, the transition to double-positive [DP] stage), allelic exclusion of the TCR beta chain gene locus, rearrangement of the TCR alpha genes, and cellular expansion [<a href="#rid112">112,113</a>]. No ligand for the pre-TCR has been identified, and T cells can develop with a pre-TCR that has no external domains [<a href="#rid118">118</a>], suggesting that pre-TCR signaling is cell autonomous. (See  <a class="medical medical_review" href="/d/html/3950.html" rel="external">"T-B-NK+ SCID: Pathogenesis, clinical manifestations, and diagnosis", section on 'T cell receptor generation'</a>.)</p><p>If a thymocyte does not produce any functional alpha chains, it cannot develop further, and dies via apoptosis after three to four days. If alpha gene rearrangement is successful, alpha chains assemble with beta chains and are expressed on the surface as a complete alpha-beta TCR-CD3 receptor complex. The CD4 and CD8 antigens next appear at low levels on the surface, and the cell has the phenotype TCRloCD3loCD4loCD8lo.</p><p class="headingAnchor" id="H1231735"><span class="h3">T cell co-receptors CD4 and CD8</span><span class="headingEndMark"> — </span>The surface antigens CD4 and CD8 distinguish two major subsets of CD3-positive T cells. Normal mature cells express either one of these molecules, but not both. The CD8 antigen is required for T cell interaction with cells expressing MHC class I molecules, while CD4 is necessary for interaction with cells expressing MHC class II. (See  <a class="medical medical_review" href="/d/html/3969.html" rel="external">"Major histocompatibility complex (MHC) structure and function"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>CD4 is a 55 kD transmembrane glycoprotein encoded by a gene on chromosome 12. It is a member of the immunoglobulin (Ig) superfamily and has four extracellular Ig-like domains. The outermost two domains of CD4 interact with a monomorphic determinant of MHC class II molecules. CD4 is also a receptor for interleukin-16, which acts as a chemoattractant factor for cells that express CD4 [<a href="#rid119">119</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CD8 is made up of two polypeptides designated alpha and beta. Both chains have a Mr of 32 kD and are encoded by genes on chromosome 2. CD8 binds to the membrane-proximal domain of MHC class I molecules. Most CD8 on T cells is in the form of alpha-beta heterodimers, but it also occurs as an alpha2 homodimer. Both forms are functional, but they behave differently with respect to signal transduction and their roles in T cell development.</p><p></p><p>The cytoplasmic domains of both CD4 and CD8 are associated with the protein tyrosine kinase Lck, a member of the src family of tyrosine kinases. CD4 and CD8 associate with Lck in slightly different fashions, but both molecules are important co-stimulators in T cell activation. (See  <a class="medical medical_review" href="/d/html/3980.html" rel="external">"The adaptive cellular immune response: T cells and cytokines"</a>.)</p><p>The mechanism whereby gamma-delta or alpha-beta lineage commitment is determined is unknown. There are data to suggest that expression of a functional gamma-delta receptor precludes further development along the alpha-beta path [<a href="#rid120">120</a>].</p><p class="headingAnchor" id="H1231784"><span class="h3">Late thymic phase</span><span class="headingEndMark"> — </span>Cells that fail to interact with self-MHC die by apoptosis. Following positive selection (see below), the T cells become DP cells (ie, TCRhiCD3hiCD4hiCD8hi). At this stage, alpha gene rearrangement ceases (see  <a class="medical medical_review" href="/d/html/3980.html" rel="external">"The adaptive cellular immune response: T cells and cytokines"</a>). DP cells are the targets of the selective processes that establish the repertoire of TCR specificities. In the final phase of thymic T cell development, cells become single-positive (SP), ie, they express only CD4 (MHC class II-restricted) or CD8 (MHC class I-restricted)  (<a class="graphic graphic_figure graphicRef76102" href="/d/graphic/76102.html" rel="external">figure 3</a>). What regulates the transition of thymocytes from DP to SP is not known. The process may be either random or controlled by specific cellular interactions. Neither the random nor the instructive models have been firmly established.</p><p class="headingAnchor" id="H1231827"><span class="h2">T cell repertoire</span><span class="headingEndMark"> — </span>The concept of the T cell repertoire is identical to that of the B cell repertoire. (See <a class="local">'B cell development'</a> above.)</p><p>However, due to the different ways in which B cells and T cells interact with antigen, the set of antigenic determinants recognized by each cell type is different (although not necessarily mutually exclusive, as some epitopes may be recognized by both) [<a href="#rid121">121</a>]. In order for the immune system to be effective, T cells must be able to recognize the multitude of foreign molecules the body encounters without attacking self.</p><p class="headingAnchor" id="H1231865"><span class="h3">Positive selection</span><span class="headingEndMark"> — </span>The MHC molecules expressed in the thymus determine the spectrum of antigens that T cells can recognize, a limitation referred to as MHC restriction. This same restriction extends to the ability of T cells to cooperate in immune responses, for example, in providing help to B cells. (See  <a class="medical medical_review" href="/d/html/3975.html" rel="external">"The adaptive humoral immune response"</a>.)</p><p>MHC restriction results from the process of positive selection in the thymus (positive because T cells live as a result). Positive selection is mediated mainly through weak interactions between TCRs expressed on thymocytes and self-peptides presented through MHC antigens expressed on thymic epithelial cells [<a href="#rid122">122</a>], many of which are of neural crest origin. Positive selection rescues thymocytes from apoptosis, which is the fate of the vast majority of developing T cells.</p><p class="headingAnchor" id="H1231902"><span class="h3">Negative selection</span><span class="headingEndMark"> — </span>Negative selection results from high affinity interactions of developing T cells with self-peptides presented on MHC antigens. This process prevents the survival of T cells that, if released into the periphery, could activate autoimmune responses. Bone marrow-derived antigen-presenting cells (eg, thymic dendritic cells, macrophages) appear to be important in negative selection.</p><p>As a result of positive and negative selection, only 1 to 5 percent of thymocytes exit the thymus as mature T cells; the remainder die [<a href="#rid123">123</a>].</p><p class="headingAnchor" id="H1231927"><span class="h3">The mature phase</span><span class="headingEndMark"> — </span>Mature thymocytes exit the thymus through venules in the medulla and recirculate through the blood, secondary lymphoid organs and lymph, surveying the body for foreign antigens.</p><p>Thymic output of T cells can be evaluated with T cell-receptor rearrangement excision circle (TREC) analysis. These are analogous to the kappa rearrangement excision circles (KRECs) described above. (See <a class="local">'Immature B cells'</a> above.)</p><p>TRECs are formed during TCR rearrangement in the thymus when loops of DNA are excised from the chromosome. These excision circles are stable and are not replicated during subsequent mitoses; hence, they are diluted out in the peripheral blood T cell compartment with each cell division. Cell populations with high numbers of TRECs are recent thymic emigrants [<a href="#rid124">124,125</a>]. TREC measurement in dried blood spots is an established method of newborn screening for severe autologous T cell lymphopenia (severe combined immunodeficiency, or SCID) and is available in the United States [<a href="#rid126">126</a>]. (See  <a class="medical medical_review" href="/d/html/16363.html" rel="external">"Newborn screening for inborn errors of immunity", section on 'Overview of TREC screening test'</a> and  <a class="medical medical_review" href="/d/html/3955.html" rel="external">"Severe combined immunodeficiency (SCID): An overview", section on 'Newborn screening'</a>.)</p><p>T cells have a long life span. Upon antigen stimulation, T cells enlarge and undergo rapid proliferation. After stimulation, T cells become effector cells. Some T cells also become memory cells, analogous to memory B cells. These aspects of the antigen-dependent development of T cells are discussed separately. (See  <a class="medical medical_review" href="/d/html/3980.html" rel="external">"The adaptive cellular immune response: T cells and cytokines"</a>.)</p><p class="headingAnchor" id="H1231972"><span class="h3">Development of gamma-delta cells</span><span class="headingEndMark"> — </span>Gamma-delta receptor-bearing T cells are the first to appear during ontogeny in all species [<a href="#rid120">120</a>]. Mature gamma-delta T cells are mainly DN cells (expressing neither CD4 nor CD8) and do not pass through the same DP stage of development as alpha-beta T cells. As with alpha-beta T cells, some speculate that the TCRs of gamma-delta T cells generate autonomous signals that drive cells through certain developmental checkpoints. While the development of gamma-delta T cells clearly requires signals mediated by gamma-delta TCRs, these signals appear to be qualitatively very different from those that drive alpha-beta cell development.</p><p>Gamma-delta T cells undergo little cellular expansion within the thymus but may expand considerably in the periphery. The extent to which gamma-delta T cells undergo positive and/or negative selection is unknown [<a href="#rid120">120</a>]. Some reports support the existence of versions of these processes that are involved in gamma-delta T cell development, but the experimental systems are not clearly physiologic in many instances. One study strongly suggests that an autosomal dominant gene variant expressed in the thymus can mediate positive selection of a population of murine cutaneous gamma-delta T cells [<a href="#rid127">127</a>].</p><p class="headingAnchor" id="H1232021"><span class="h2">Characteristics of mature T cells</span><span class="headingEndMark"> — </span>This section applies principally to cells expressing alpha-beta TCRs. Mature T cells are small lymphocytes with an appearance identical to other lymphocyte subpopulations. They recirculate continually from blood to lymphoid tissues to lymph, awaiting contact with antigen presenting cells that bear a complementary peptide-MHC complex. Most functional studies of mature T cells have been conducted in mice; these studies are largely believed to be relevant to humans, but there are important differences in the origins and maintenance of T cells in mice and humans with aging [<a href="#rid128">128</a>]. Even in aged mice, most naïve T cells are of thymic origin, whereas in humans, even before thymic involution, most naïve T cells are derived from proliferation of T cells in peripheral tissues. Furthermore, the lifespan of naïve T cells in mice is 6 to 10 weeks, whereas in humans naïve T cells can live for 5 to 10 years [<a href="#rid128">128</a>].</p><p>All mature thymocytes and peripheral blood T cells bear the CD2, CD3 T cell receptor complex, CD5, and CD28 antigens  (<a class="graphic graphic_table graphicRef50154" href="/d/graphic/50154.html" rel="external">table 5</a>). Other surface molecules such as CD4 and CD8, as well as cytokine and chemokine receptors serve to differentiate several functionally distinct subpopulations of mature T cells. As described above, these subsets may differ in their interactions with various classes of self-histocompatibility proteins. In addition, they may have very different functions in immune responses. Subpopulations of mature T cells are similar morphologically; markers are required for their distinction.</p><p>There are two principal categories of CD4 T cells: T cells that modulate the activity of B cells and other T cells, either by stimulating (helper T cells) or suppressing (regulatory T cells or Tregs) immune responses, and effector cells mediating cellular immune responses (cytotoxic T cells, Tc; or cytotoxic T lymphocytes, CTLs), but other subpopulations are also recognized. While most regulatory T cells express CD4, and most cytotoxic T cells express CD8, there are exceptions. Cytotoxic T cells expressing CD4 are prominent in graft rejection and have also been observed in tumor immune responses [<a href="#rid129">129</a>]. Cytokine producing cells expressing CD8 may also be seen in certain normal or pathologic immune responses [<a href="#rid130">130,131</a>].</p><p class="headingAnchor" id="H3188394906"><span class="h3">Origins of T subsets</span><span class="headingEndMark"> — </span>Naïve T cells of three major types develop in the thymus: MHC class II restricted CD4+ T helper cells, MHC class II restricted CD4+ Tregs (defined by expression of the transcription factor FoxP3 and the high affinity IL-2 receptor), and MHC class I restricted CD8+ T cells. Naïve CD4+ T helper cells, once stimulated by antigen expressed on activated antigen presenting cells (eg, dendritic cells or B cells) in the context of self-MHC class II molecules, can acquire several different effector functions, each associated with expression of particular cytokines and other proteins, as described below. How antigen-stimulated CD4+ T helper cells "choose" what type of effector cells they become in response to different immune stimuli remains an area of ongoing research. Certain key transcription factors contribute to fate selection; for example, Tbet is required for the production of Th1 cells. However, Tbet also influences the differentiation of CD8+ T cells [<a href="#rid132">132</a>], and even within particular CD4+ T cell subsets there appears to be substantial plasticity, particularly in humans [<a href="#rid133">133</a>]. Thus, rather than being terminally differentiated cell fates, different T helper cell types may be better thought of as cell states that can be modulated during the course of immune responses.</p><p class="headingAnchor" id="H1232084"><span class="h3">Cytotoxic T cells</span><span class="headingEndMark"> — </span>Cytotoxic T cells (Tc) express mainly CD8, and lyse autologous cells bearing foreign antigen molecules associated with class I histocompatibility proteins or cells that are allogeneic with respect to MHC class I. CD4+ cytotoxic T cells are recognized [<a href="#rid134">134</a>], but the function of these cells is less certain; they may participate in graft rejection and in tumor immune responses in which antigen is presented in the context of allogeneic MHC class II molecules [<a href="#rid129">129</a>].</p><p>A discussion of alloreactivity can be found elsewhere. (See  <a class="medical medical_review" href="/d/html/3980.html" rel="external">"The adaptive cellular immune response: T cells and cytokines"</a>.)</p><p class="headingAnchor" id="H1232109"><span class="h3">T helper cells</span><span class="headingEndMark"> — </span>T helper cells generally express CD4 and recognize antigens associated with MHC class II molecules. Subtypes of CD4+ T cells have been defined, including Th1 and Th2 T helper cells, T follicular helper (Tfh) cells, Th9 cells, and Th17 cells. These cells are distinguished by the cytokines they produce and by certain surface markers. An "undifferentiated" mature T cell, referred to as Th0, may develop into various kinds of effector cells, depending upon the cytokines they are exposed to during antigen stimulation.</p><p class="headingAnchor" id="H1232122"><span class="h4">Th1 cells</span><span class="headingEndMark"> — </span>Th1 cells predominantly generate delayed hypersensitivity reactions, although they also can provide B cell help. (See  <a class="medical medical_review" href="/d/html/3980.html" rel="external">"The adaptive cellular immune response: T cells and cytokines"</a>.)</p><p class="headingAnchor" id="H1232147"><span class="h4">Th2 cells</span><span class="headingEndMark"> — </span>Th2 are prominent helpers for antibody production, especially IgE responses, and promote eosinophil development and activity. (See  <a class="medical medical_review" href="/d/html/5542.html" rel="external">"The biology of IgE", section on 'Regulation of synthesis'</a>.)</p><p class="headingAnchor" id="H1232172"><span class="h4">Regulatory T cells (Tregs)</span><span class="headingEndMark"> — </span>Tregs are distinguished by expression of the transcription factor FoxP3, which appears to be a "master" gene for the development and function of this type of T cell. Tregs also express CD25 (the IL-2 receptor alpha chain) and are dependent on IL-2. CD4+CD25+FoxP3+ Tregs are important in countering the development of allergic and autoimmune disease, as FoxP3 mutant mice and humans develop airway inflammation, eosinophilia, and elevated serum IgE levels. (See  <a class="medical medical_review" href="/d/html/3924.html" rel="external">"IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked"</a>.)</p><p>Tregs have also been implicated in the prevention of graft rejection and graft versus host disease (GVHD) [<a href="#rid135">135</a>]. (See  <a class="medical medical_review" href="/d/html/3546.html" rel="external">"Biology of the graft-versus-tumor effect following hematopoietic cell transplantation", section on 'Regulatory T cells'</a>.)</p><p class="headingAnchor" id="H2874494194"><span class="h4">Follicular T cells (Tfh cells)</span><span class="headingEndMark"> — </span>T cell help is required for germinal center B cells to undergo somatic hypermutation and mature into cells expressing high affinity antibodies. This help is provided by specialized follicular helper T cells (so-called Tfh cells) [<a href="#rid136">136</a>]. Like germinal center B cells, the development of Tfh cells depends on the transcription factor Bcl6, and also appears to require Notch signaling triggered by the Notch ligand DLL4, which is expressed on follicular dendritic cells [<a href="#rid137">137</a>]. Like other T helper cells, Tfh cells express CD4 and several other distinguishing markers, including CXCR5, CXCR13, PD-1, SAP (SH2D1A), IL-21, and ICOS. Tfh cells are not only important for the formation of germinal centers, but also maintenance of germinal centers as well as the differentiation of germinal center B cells into plasma cells and memory B cells. In addition, a circulating pool of memory Tfh cells has also been described that may contribute to secondary immune responses following re-exposure to antigen [<a href="#rid85">85</a>].</p><p class="headingAnchor" id="H24003629"><span class="h4">Th9 cells</span><span class="headingEndMark"> — </span>Th9 cells express IL-9 and have been implicated in tumor immunity, but their functions are not well-characterized [<a href="#rid138">138</a>]. In some mouse models, Th9 cells have strong anti-tumor activity even after depletion of CD8+ cytotoxic T cells [<a href="#rid139">139</a>].</p><p class="headingAnchor" id="H1232221"><span class="h4">Th17 cells</span><span class="headingEndMark"> — </span>Th17 cells are proinflammatory T cells implicated in the cell-mediated cytotoxicity of some autoimmune diseases, many of which were formerly thought to be Th1-mediated [<a href="#rid140">140-142</a>]. Th17 cells produce IL-17, IL-22, IL-26, IFN-gamma, and CCL20 and express IL-23 receptor and CD45RO. In humans, differentiation of Th0 cells into Th17 cells requires exposure to IL-1beta and either IL-23 or IL-6 [<a href="#rid143">143-145</a>]. ROR-gamma t is a transcription factor that regulates this T cell subset. (See  <a class="medical medical_review" href="/d/html/3980.html" rel="external">"The adaptive cellular immune response: T cells and cytokines"</a>.)</p><p>Th17 cells may have some role in certain types of asthma, although patients with Th17-mediated asthma are not atopic and inflammatory cells in the airway are predominately neutrophils, rather than eosinophils [<a href="#rid146">146</a>]. Th17 cells may also be involved in allergic rhinitis and conjunctivitis, food protein induced enterocolitis, atopic dermatitis, contact dermatitis, and are essential for effective mucosal immunity against fungi (eg, Candida species) [<a href="#rid145">145,147</a>]. </p><p class="headingAnchor" id="H1265604"><span class="h3">Naïve T cells</span><span class="headingEndMark"> — </span>CD45, also called "leukocyte common antigen," is a protein tyrosine phosphatase that has a critical role in T cell activation via the dephosphorylation of the tyrosine kinase Lck (see  <a class="medical medical_review" href="/d/html/3980.html" rel="external">"The adaptive cellular immune response: T cells and cytokines"</a>). Different CD45 isoforms are expressed at different stages of lymphocyte development, making it a useful marker for lymphocyte subtyping. Naïve T cells express an isoform of CD45 called CD45RA, and are negative for a second isoform, CD45RO, that is expressed following activation (see below).</p><p class="headingAnchor" id="H1263084"><span class="h3">T cell activation markers</span><span class="headingEndMark"> — </span>T cells express a variety of surface molecules after activation via the antigen receptor. These include CD69, CD40 ligand, CD28, CD25, MHC class II, and an isoform of CD45 called CD4RO. </p><p class="headingAnchor" id="H1265553"><span class="h3">Memory T cells</span><span class="headingEndMark"> — </span>T cell immune responses in mice and humans occur in three phases: clonal expansion and differentiation of antigen-specific T cells; cessation, during which most effector T cells die by apoptosis; and memory, marked by the persistence of a subpopulation of antigen-primed T cells. Memory T cells express CD45RO and (like memory B cells) CD27. In humans, memory T cells against antigens such as viral vaccines are proportional to the extent of the initial immune response, typically constituting approximately 5 percent of the responding cells, and may persist for as much as 25 years or more after the initial exposure [<a href="#rid128">128</a>]. The proportions of naïve versus activated or memory T cells may have clinical applications in the diagnosis of autoimmune or inflammatory conditions and immunodeficiency [<a href="#rid148">148</a>].</p><p>As humans age and naïve T cell numbers decline, memory T cells constitute a larger fraction of the T cell complement. This appears to be particularly true for tissue-resident quiescent memory T cells that express CD69, which are found in many human tissues and have a unique transcriptional signature [<a href="#rid149">149</a>]. It is proposed that upon activation, these tissue resident memory cells have the potential to give rise to T cells with helper, cytotoxic, and regulatory functions.</p><p class="headingAnchor" id="H5924629"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description</strong> – There are two major lymphocyte lineages: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>B lymphocytes </p><p class="bulletIndent2"><span class="glyph">•</span>T lymphocytes</p><p></p><p class="bulletIndent1">Natural killer (NK) cells, innate lymphoid cells, and myeloid lineages that cooperate with B and T lymphocytes in the innate and adaptive immune systems are discussed separately. (See  <a class="medical medical_review" href="/d/html/13572.html" rel="external">"An overview of the innate immune system"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Origin of lymphocytes</strong> – Highly proliferative lymphoid-committed progenitor cells arise from bone marrow hematopoietic stem cells. (See <a class="local">'Origin of lymphoid cells'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Normal lymphoid tissues</strong>. (See <a class="local">'Normal lymphoid tissues'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Primary lymphoid organs</strong> – B and T lymphocytes are initially generated in bone marrow and thymus, respectively.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Secondary lymphoid organs</strong> – Lymph nodes, spleen, tonsils, and lymphoid tissue in the gastrointestinal and respiratory tracts. B cells are mainly located in follicles and T cells in interfollicular areas of these sites.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>B cells</strong> — New B cells are generated throughout life. After birth, lymphoid development occurs in bone marrow. Mature B cells leave the marrow and migrate to secondary lymphoid tissues where they interact with exogenous antigen and/or T helper cells; these steps constitute the "antigen-dependent phase" of B cell development. (See <a class="local">'B cell development'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immunoglobulin (Ig) rearrangement</strong> – Productive rearrangement of Ig heavy chain and light chain genes is essential for early stages of B cell development and for later mature B cell maturation. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Maturation stages</strong> – B lymphocytes further mature as: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Pro-B cells (see <a class="local">'Pro-B cells'</a> above)</p><p class="bulletIndent3"><span class="glyph">-</span>Pre-B cells (see <a class="local">'Pre-B cells'</a> above)</p><p class="bulletIndent3"><span class="glyph">-</span>Immature B cells (see <a class="local">'Immature B cells'</a> above)</p><p class="bulletIndent3"><span class="glyph">-</span>Mature B cells (see <a class="local">'Mature B cells'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>B cell subsets </strong>– Include (see <a class="local">'B cell subsets'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>CD5 negative ("conventional" B cells)</p><p class="bulletIndent3"><span class="glyph">-</span>CD5 positive (B-1 cells) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Activation and maturation</strong> – B cell activation and maturation are described above. (See <a class="local">'B cell activation'</a> above and <a class="local">'Maturation of activated B cells'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Plasma cells</strong> – Large cells that produce large quantities of Igs. (See <a class="local">'Plasma cells'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Memory B cells</strong> – Long-lived cells that are sensitive to antigen stimulation and rapidly proliferate to generate plasma cells. (See <a class="local">'Memory B cells'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>T lymphocytes</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>T cell lineages</strong> – T lymphocytes express CD3, the T cell receptor (TCR). More than 95 percent express TCR alpha and beta chains; others express TCR gamma and delta chains. (See <a class="local">'T cell lineages'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>T cell development</strong> – T cell progenitors migrate from bone marrow to thymus, where intrinsic functions provided by transcription factors and extrinsic signals provided by soluble factors and cell-cell interactions are required for maturation. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>T cell subsets</strong> – Defined by the following cell surface antigens (see <a class="local">'T cell co-receptors CD4 and CD8'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>CD4 </p><p class="bulletIndent3"><span class="glyph">-</span>CD8 </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>T cell repertoire</strong> – Positive selection and negative selection contribute to the diversity of T lymphocytes. (See <a class="local">'T cell repertoire'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cytotoxic T cells </strong>– CD8-expressing T cells that lyse autologous cells bearing foreign antigen molecules associated with class I histocompatibility proteins (MHC) or cells that are allogeneic with respect to MHC class I. (See <a class="local">'Cytotoxic T cells'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>T helper cells</strong> – T cells that express CD4 and recognize antigens associated with MHC class II molecules. (See <a class="local">'T helper cells'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Naïve T cells</strong> – T cells that are not yet antigen primed. (See <a class="local">'Naïve T cells'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Memory T cells</strong> – Antigen-primed T cells that can persist for decades. (See <a class="local">'Memory T cells'</a> above.)</p><p></p><p class="headingAnchor" id="H1596063853"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Francisco A Bonilla, MD, PhD, who contributed as an author, and E Richard Stiehm, MD, who contributed as a Section Editor to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 2022; 140:1229.</a></li><li><a class="nounderline abstract_t">Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022; 36:1720.</a></li><li><a class="nounderline abstract_t">Rodda LB, Lu E, Bennett ML, et al. Single-Cell RNA Sequencing of Lymph Node Stromal Cells Reveals Niche-Associated Heterogeneity. Immunity 2018; 48:1014.</a></li><li><a class="nounderline abstract_t">Dzierzak E, Bigas A. Blood Development: Hematopoietic Stem Cell Dependence and Independence. Cell Stem Cell 2018; 22:639.</a></li><li><a class="nounderline abstract_t">Yona S, Kim KW, Wolf Y, et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity 2013; 38:79.</a></li><li><a class="nounderline abstract_t">Ginhoux F, Greter M, Leboeuf M, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 2010; 330:841.</a></li><li><a class="nounderline abstract_t">Bertrand JY, Chi NC, Santoso B, et al. Haematopoietic stem cells derive directly from aortic endothelium during development. Nature 2010; 464:108.</a></li><li><a class="nounderline abstract_t">Kissa K, Herbomel P. Blood stem cells emerge from aortic endothelium by a novel type of cell transition. Nature 2010; 464:112.</a></li><li><a class="nounderline abstract_t">Ditadi A, Sturgeon CM, Tober J, et al. Human definitive haemogenic endothelium and arterial vascular endothelium represent distinct lineages. Nat Cell Biol 2015; 17:580.</a></li><li><a class="nounderline abstract_t">Rothenberg EV. Transcriptional control of early T and B cell developmental choices. Annu Rev Immunol 2014; 32:283.</a></li><li><a class="nounderline abstract_t">Dykstra B, Kent D, Bowie M, et al. Long-term propagation of distinct hematopoietic differentiation programs in vivo. Cell Stem Cell 2007; 1:218.</a></li><li><a class="nounderline abstract_t">Benz C, Copley MR, Kent DG, et al. Hematopoietic stem cell subtypes expand differentially during development and display distinct lymphopoietic programs. Cell Stem Cell 2012; 10:273.</a></li><li><a class="nounderline abstract_t">Nuñez C, Nishimoto N, Gartland GL, et al. B cells are generated throughout life in humans. J Immunol 1996; 156:866.</a></li><li><a class="nounderline abstract_t">LeBien TW, Tedder TF. B lymphocytes: how they develop and function. Blood 2008; 112:1570.</a></li><li><a class="nounderline abstract_t">Björck P, Kincade PW. CD19+ pro-B cells can give rise to dendritic cells in vitro. J Immunol 1998; 161:5795.</a></li><li><a class="nounderline abstract_t">Dorshkind K, Montecino-Rodriguez E. Fetal B-cell lymphopoiesis and the emergence of B-1-cell potential. Nat Rev Immunol 2007; 7:213.</a></li><li><a class="nounderline abstract_t">Matsuda F, Ishii K, Bourvagnet P, et al. The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus. J Exp Med 1998; 188:2151.</a></li><li><a class="nounderline abstract_t">Gauld SB, Dal Porto JM, Cambier JC. B cell antigen receptor signaling: roles in cell development and disease. Science 2002; 296:1641.</a></li><li><a class="nounderline abstract_t">Tedder TF, Zhou LJ, Engel P. The CD19/CD21 signal transduction complex of B lymphocytes. Immunol Today 1994; 15:437.</a></li><li><a class="nounderline abstract_t">He XY, Antao VP, Basila D, et al. Isolation and molecular characterization of the human CD34 gene. Blood 1992; 79:2296.</a></li><li><a class="nounderline abstract_t">Melchers F, Karasuyama H, Haasner D, et al. The surrogate light chain in B-cell development. Immunol Today 1993; 14:60.</a></li><li><a class="nounderline abstract_t">Schuh W, Meister S, Roth E, Jäck HM. Cutting edge: signaling and cell surface expression of a mu H chain in the absence of lambda 5: a paradigm revisited. J Immunol 2003; 171:3343.</a></li><li><a class="nounderline abstract_t">Yel L, Minegishi Y, Coustan-Smith E, et al. Mutations in the mu heavy-chain gene in patients with agammaglobulinemia. N Engl J Med 1996; 335:1486.</a></li><li><a class="nounderline abstract_t">Minegishi Y, Coustan-Smith E, Wang YH, et al. Mutations in the human lambda5/14.1 gene result in B cell deficiency and agammaglobulinemia. J Exp Med 1998; 187:71.</a></li><li><a class="nounderline abstract_t">Minegishi Y, Coustan-Smith E, Rapalus L, et al. Mutations in Igalpha (CD79a) result in a complete block in B-cell development. J Clin Invest 1999; 104:1115.</a></li><li><a class="nounderline abstract_t">Ferrari S, Lougaris V, Caraffi S, et al. Mutations of the Igbeta gene cause agammaglobulinemia in man. J Exp Med 2007; 204:2047.</a></li><li><a class="nounderline abstract_t">Vetrie D, Vorechovský I, Sideras P, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 1993; 361:226.</a></li><li><a class="nounderline abstract_t">Minegishi Y, Rohrer J, Coustan-Smith E, et al. An essential role for BLNK in human B cell development. Science 1999; 286:1954.</a></li><li><a class="nounderline abstract_t">Schweighoffer E, Vanes L, Mathiot A, et al. Unexpected requirement for ZAP-70 in pre-B cell development and allelic exclusion. Immunity 2003; 18:523.</a></li><li><a class="nounderline abstract_t">Cossman J, Neckers LM, Arnold A, Korsmeyer SJ. Induction of differentiation in a case of common acute lymphoblastic leukemia. N Engl J Med 1982; 307:1251.</a></li><li><a class="nounderline abstract_t">Nadler LM, Ritz J, Bates MP, et al. Induction of human B cell antigens in non-T cell acute lymphoblastic leukemia. J Clin Invest 1982; 70:433.</a></li><li><a class="nounderline abstract_t">Shipp MA, Richardson NE, Sayre PH, et al. Molecular cloning of the common acute lymphoblastic leukemia antigen (CALLA) identifies a type II integral membrane protein. Proc Natl Acad Sci U S A 1988; 85:4819.</a></li><li><a class="nounderline abstract_t">Shipp MA, Vijayaraghavan J, Schmidt EV, et al. Common acute lymphoblastic leukemia antigen (CALLA) is active neutral endopeptidase 24.11 ("enkephalinase"): direct evidence by cDNA transfection analysis. Proc Natl Acad Sci U S A 1989; 86:297.</a></li><li><a class="nounderline abstract_t">Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994; 15:450.</a></li><li><a class="nounderline abstract_t">Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005; 8:140.</a></li><li><a class="nounderline abstract_t">Hemler ME. VLA proteins in the integrin family: structures, functions, and their role on leukocytes. Annu Rev Immunol 1990; 8:365.</a></li><li><a class="nounderline abstract_t">Ryan DH, Nuccie BL, Abboud CN, Winslow JM. Vascular cell adhesion molecule-1 and the integrin VLA-4 mediate adhesion of human B cell precursors to cultured bone marrow adherent cells. J Clin Invest 1991; 88:995.</a></li><li><a class="nounderline abstract_t">Durie FH, Foy TM, Masters SR, et al. The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol Today 1994; 15:406.</a></li><li><a class="nounderline abstract_t">Armitage RJ, Fanslow WC, Strockbine L, et al. Molecular and biological characterization of a murine ligand for CD40. Nature 1992; 357:80.</a></li><li><a class="nounderline abstract_t">Nitschke L, Tsubata T. Molecular interactions regulate BCR signal inhibition by CD22 and CD72. Trends Immunol 2004; 25:543.</a></li><li><a class="nounderline abstract_t">van Zelm MC, van der Burg M, Langerak AW, van Dongen JJ. PID comes full circle: applications of V(D)J recombination excision circles in research, diagnostics and newborn screening of primary immunodeficiency disorders. Front Immunol 2011; 2:12.</a></li><li><a class="nounderline abstract_t">Pillai S, Cariappa A. The follicular versus marginal zone B lymphocyte cell fate decision. Nat Rev Immunol 2009; 9:767.</a></li><li><a class="nounderline abstract_t">Cerutti A, Cols M, Puga I. Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes. Nat Rev Immunol 2013; 13:118.</a></li><li><a class="nounderline abstract_t">GOWANS JL, KNIGHT EJ. THE ROUTE OF RE-CIRCULATION OF LYMPHOCYTES IN THE RAT. Proc R Soc Lond B Biol Sci 1964; 159:257.</a></li><li><a class="nounderline abstract_t">Gallatin WM, Weissman IL, Butcher EC. A cell-surface molecule involved in organ-specific homing of lymphocytes. Nature 1983; 304:30.</a></li><li><a class="nounderline abstract_t">Goldstein LA, Zhou DF, Picker LJ, et al. A human lymphocyte homing receptor, the hermes antigen, is related to cartilage proteoglycan core and link proteins. Cell 1989; 56:1063.</a></li><li><a class="nounderline abstract_t">St John T, Meyer J, Idzerda R, Gallatin WM. Expression of CD44 confers a new adhesive phenotype on transfected cells. Cell 1990; 60:45.</a></li><li><a class="nounderline abstract_t">Stamenkovic I, Amiot M, Pesando JM, Seed B. A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell 1989; 56:1057.</a></li><li><a class="nounderline abstract_t">Stoolman LM. Adhesion molecules controlling lymphocyte migration. Cell 1989; 56:907.</a></li><li><a class="nounderline abstract_t">Tedder TF, Penta AC, Levine HB, Freedman AS. Expression of the human leukocyte adhesion molecule, LAM1. Identity with the TQ1 and Leu-8 differentiation antigens. J Immunol 1990; 144:532.</a></li><li><a class="nounderline abstract_t">Spertini O, Freedman AS, Belvin MP, et al. Regulation of leukocyte adhesion molecule-1 (TQ1, Leu-8) expression and shedding by normal and malignant cells. Leukemia 1991; 5:300.</a></li><li><a class="nounderline abstract_t">Siegelman MH, van de Rijn M, Weissman IL. Mouse lymph node homing receptor cDNA clone encodes a glycoprotein revealing tandem interaction domains. Science 1989; 243:1165.</a></li><li><a class="nounderline abstract_t">Springer TA. Adhesion receptors of the immune system. Nature 1990; 346:425.</a></li><li><a class="nounderline abstract_t">Astier AL, Xu R, Svoboda M, et al. Temporal gene expression profile of human precursor B leukemia cells induced by adhesion receptor: identification of pathways regulating B-cell survival. Blood 2003; 101:1118.</a></li><li><a class="nounderline abstract_t">Kuijpers TW, Bende RJ, Baars PA, et al. CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Invest 2010; 120:214.</a></li><li><a class="nounderline abstract_t">Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. Blood 2008; 111:3941.</a></li><li><a class="nounderline abstract_t">Carroll MC. The role of complement in B cell activation and tolerance. Adv Immunol 2000; 74:61.</a></li><li><a class="nounderline abstract_t">Freedman AS, Munro JM, Rice GE, et al. Adhesion of human B cells to germinal centers in vitro involves VLA-4 and INCAM-110. Science 1990; 249:1030.</a></li><li><a class="nounderline abstract_t">Li L, Zhang X, Kovacic S, et al. Identification of a human follicular dendritic cell molecule that stimulates germinal center B cell growth. J Exp Med 2000; 191:1077.</a></li><li><a class="nounderline abstract_t">Lu E, Wolfreys FD, Muppidi JR, et al. S-Geranylgeranyl-L-glutathione is a ligand for human B cell-confinement receptor P2RY8. Nature 2019; 567:244.</a></li><li><a class="nounderline abstract_t">Grammer AC, Slota R, Fischer R, et al. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest 2003; 112:1506.</a></li><li><a class="nounderline abstract_t">Van de Velde H, von Hoegen I, Luo W, et al. The B-cell surface protein CD72/Lyb-2 is the ligand for CD5. Nature 1991; 351:662.</a></li><li><a class="nounderline abstract_t">Bikah G, Carey J, Ciallella JR, et al. CD5-mediated negative regulation of antigen receptor-induced growth signals in B-1 B cells. Science 1996; 274:1906.</a></li><li><a class="nounderline abstract_t">Youinou P, Jamin C, Lydyard PM. CD5 expression in human B-cell populations. Immunol Today 1999; 20:312.</a></li><li><a class="nounderline abstract_t">Nisitani S, Murakami M, Akamizu T, et al. Preferential localization of human CD5+ B cells in the peritoneal cavity. Scand J Immunol 1997; 46:541.</a></li><li><a class="nounderline abstract_t">Bofill M, Janossy G, Janossa M, et al. Human B cell development. II. Subpopulations in the human fetus. J Immunol 1985; 134:1531.</a></li><li><a class="nounderline abstract_t">Hannet I, Erkeller-Yuksel F, Lydyard P, et al. Developmental and maturational changes in human blood lymphocyte subpopulations. Immunol Today 1992; 13:215, 218.</a></li><li><a class="nounderline abstract_t">Lydyard PM, Quartey-Papafio R, Bröker B, et al. The antibody repertoire of early human B cells. I. High frequency of autoreactivity and polyreactivity. Scand J Immunol 1990; 31:33.</a></li><li><a class="nounderline abstract_t">Chen ZJ, Wheeler J, Notkins AL. Antigen-binding B cells and polyreactive antibodies. Eur J Immunol 1995; 25:579.</a></li><li><a class="nounderline abstract_t">Casali P, Notkins AL. Probing the human B-cell repertoire with EBV: polyreactive antibodies and CD5+ B lymphocytes. Annu Rev Immunol 1989; 7:513.</a></li><li><a class="nounderline abstract_t">Ehrenstein MR, Notley CA. The importance of natural IgM: scavenger, protector and regulator. Nat Rev Immunol 2010; 10:778.</a></li><li><a class="nounderline abstract_t">Chou MY, Fogelstrand L, Hartvigsen K, et al. Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. J Clin Invest 2009; 119:1335.</a></li><li><a class="nounderline abstract_t">Ueki Y, Goldfarb IS, Harindranath N, et al. Clonal analysis of a human antibody response. Quantitation of precursors of antibody-producing cells and generation and characterization of monoclonal IgM, IgG, and IgA to rabies virus. J Exp Med 1990; 171:19.</a></li><li><a class="nounderline abstract_t">Mauri C, Menon M. Human regulatory B cells in health and disease: therapeutic potential. J Clin Invest 2017; 127:772.</a></li><li><a class="nounderline abstract_t">Blair PA, Noreña LY, Flores-Borja F, et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 2010; 32:129.</a></li><li><a class="nounderline abstract_t">Flores-Borja F, Bosma A, Ng D, et al. CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med 2013; 5:173ra23.</a></li><li><a class="nounderline abstract_t">Clark EA, Ledbetter JA. Structure, function, and genetics of human B cell-associated surface molecules. Adv Cancer Res 1989; 52:81.</a></li><li><a class="nounderline abstract_t">Gordon J. B-cell signalling via the C-type lectins CD23 and CD72. Immunol Today 1994; 15:411.</a></li><li><a class="nounderline abstract_t">Stokes J, Casale TB. Rationale for new treatments aimed at IgE immunomodulation. Ann Allergy Asthma Immunol 2004; 93:212.</a></li><li><a class="nounderline abstract_t">Nurieva RI, Liu X, Dong C. Yin-Yang of costimulation: crucial controls of immune tolerance and function. Immunol Rev 2009; 229:88.</a></li><li><a class="nounderline abstract_t">Liu M, Duke JL, Richter DJ, et al. Two levels of protection for the B cell genome during somatic hypermutation. Nature 2008; 451:841.</a></li><li><a class="nounderline abstract_t">Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009; 15:5494.</a></li><li><a class="nounderline abstract_t">Islam KB, Nilsson L, Sideras P, et al. TGF-beta 1 induces germ-line transcripts of both IgA subclasses in human B lymphocytes. Int Immunol 1991; 3:1099.</a></li><li><a class="nounderline abstract_t">Durandy A, Revy P, Imai K, Fischer A. Hyper-immunoglobulin M syndromes caused by intrinsic B-lymphocyte defects. Immunol Rev 2005; 203:67.</a></li><li><a class="nounderline abstract_t">Kurosaki T, Kometani K, Ise W. Memory B cells. Nat Rev Immunol 2015; 15:149.</a></li><li><a class="nounderline abstract_t">Uckun FM. Regulation of human B-cell ontogeny. Blood 1990; 76:1908.</a></li><li><a class="nounderline abstract_t">Oracki SA, Walker JA, Hibbs ML, et al. Plasma cell development and survival. Immunol Rev 2010; 237:140.</a></li><li><a class="nounderline abstract_t">Nutt SL, Fairfax KA, Kallies A. BLIMP1 guides the fate of effector B and T cells. Nat Rev Immunol 2007; 7:923.</a></li><li><a class="nounderline abstract_t">Hu CC, Dougan SK, McGehee AM, et al. XBP-1 regulates signal transduction, transcription factors and bone marrow colonization in B cells. EMBO J 2009; 28:1624.</a></li><li><a class="nounderline abstract_t">Schuber F, Lund FE. Structure and enzymology of ADP-ribosyl cyclases: conserved enzymes that produce multiple calcium mobilizing metabolites. Curr Mol Med 2004; 4:249.</a></li><li class="breakAll">WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.</li><li><a class="nounderline abstract_t">Gray D. Immunological memory: a function of antigen persistence. Trends Microbiol 1993; 1:39.</a></li><li><a class="nounderline abstract_t">Wehr C, Kivioja T, Schmitt C, et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood 2008; 111:77.</a></li><li><a class="nounderline abstract_t">van de Ven AA, van de Corput L, van Tilburg CM, et al. Lymphocyte characteristics in children with common variable immunodeficiency. Clin Immunol 2010; 135:63.</a></li><li><a class="nounderline abstract_t">Yu VW, Saez B, Cook C, et al. Specific bone cells produce DLL4 to generate thymus-seeding progenitors from bone marrow. J Exp Med 2015; 212:759.</a></li><li><a class="nounderline abstract_t">Haynes BF, Markert ML, Sempowski GD, et al. The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection. Annu Rev Immunol 2000; 18:529.</a></li><li><a class="nounderline abstract_t">Burt TD. Fetal regulatory T cells and peripheral immune tolerance in utero: implications for development and disease. Am J Reprod Immunol 2013; 69:346.</a></li><li><a class="nounderline abstract_t">van den Broek T, Delemarre EM, Janssen WJ, et al. Neonatal thymectomy reveals differentiation and plasticity within human naive T cells. J Clin Invest 2016; 126:1126.</a></li><li><a class="nounderline abstract_t">Junge S, Kloeckener-Gruissem B, Zufferey R, et al. Correlation between recent thymic emigrants and CD31+ (PECAM-1) CD4+ T cells in normal individuals during aging and in lymphopenic children. Eur J Immunol 2007; 37:3270.</a></li><li><a class="nounderline abstract_t">Pace KE, Hahn HP, Pang M, et al. CD7 delivers a pro-apoptotic signal during galectin-1-induced T cell death. J Immunol 2000; 165:2331.</a></li><li><a class="nounderline abstract_t">Krause DS, Fackler MJ, Civin CI, May WS. CD34: structure, biology, and clinical utility. Blood 1996; 87:1.</a></li><li><a class="nounderline abstract_t">Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. Molecular biological ontogenesis of the thymic reticulo-epithelial cell network during the organization of the cellular microenvironment. In Vivo 1999; 13:267.</a></li><li><a class="nounderline abstract_t">Hadden JW. Thymic endocrinology. Ann N Y Acad Sci 1998; 840:352.</a></li><li><a class="nounderline abstract_t">Rossi SW, Jenkinson WE, Anderson G, Jenkinson EJ. Clonal analysis reveals a common progenitor for thymic cortical and medullary epithelium. Nature 2006; 441:988.</a></li><li><a class="nounderline abstract_t">Bleul CC, Corbeaux T, Reuter A, et al. Formation of a functional thymus initiated by a postnatal epithelial progenitor cell. Nature 2006; 441:992.</a></li><li><a class="nounderline abstract_t">Johnson JL, Georgakilas G, Petrovic J, et al. Lineage-Determining Transcription Factor TCF-1 Initiates the Epigenetic Identity of T Cells. Immunity 2018; 48:243.</a></li><li><a class="nounderline abstract_t">Radtke F, Fasnacht N, Macdonald HR. Notch signaling in the immune system. Immunity 2010; 32:14.</a></li><li><a class="nounderline abstract_t">Schüler T, Hämmerling GJ, Arnold B. Cutting edge: IL-7-dependent homeostatic proliferation of CD8+ T cells in neonatal mice allows the generation of long-lived natural memory T cells. J Immunol 2004; 172:15.</a></li><li><a class="nounderline abstract_t">Puel A, Leonard WJ. Mutations in the gene for the IL-7 receptor result in T(-)B(+)NK(+) severe combined immunodeficiency disease. Curr Opin Immunol 2000; 12:468.</a></li><li><a class="nounderline abstract_t">Klein L, Hinterberger M, Wirnsberger G, Kyewski B. Antigen presentation in the thymus for positive selection and central tolerance induction. Nat Rev Immunol 2009; 9:833.</a></li><li><a class="nounderline abstract_t">Singh VK, Biswas S, Mathur KB, et al. Thymopentin and splenopentin as immunomodulators. Current status. Immunol Res 1998; 17:345.</a></li><li><a class="nounderline abstract_t">Haks MC, Oosterwegel MA, Blom B, et al. Cell-fate decisions in early T cell development: regulation by cytokine receptors and the pre-TCR. Semin Immunol 1999; 11:23.</a></li><li><a class="nounderline abstract_t">Anderson G, Harman BC, Hare KJ, Jenkinson EJ. Microenvironmental regulation of T cell development in the thymus. Semin Immunol 2000; 12:457.</a></li><li><a class="nounderline abstract_t">Ulrichs T, Porcelli SA. CD1 proteins: targets of T cell recognition in innate and adaptive immunity. Rev Immunogenet 2000; 2:416.</a></li><li><a class="nounderline abstract_t">Dimitroff CJ, Lee JY, Rafii S, et al. CD44 is a major E-selectin ligand on human hematopoietic progenitor cells. J Cell Biol 2001; 153:1277.</a></li><li><a class="nounderline abstract_t">Gaffen SL. Signaling domains of the interleukin 2 receptor. Cytokine 2001; 14:63.</a></li><li><a class="nounderline abstract_t">Dadi HK, Simon AJ, Roifman CM. Effect of CD3delta deficiency on maturation of alpha/beta and gamma/delta T-cell lineages in severe combined immunodeficiency. N Engl J Med 2003; 349:1821.</a></li><li><a class="nounderline abstract_t">Irving BA, Alt FW, Killeen N. Thymocyte development in the absence of pre-T cell receptor extracellular immunoglobulin domains. Science 1998; 280:905.</a></li><li><a class="nounderline abstract_t">Richmond J, Tuzova M, Cruikshank W, Center D. Regulation of cellular processes by interleukin-16 in homeostasis and cancer. J Cell Physiol 2014; 229:139.</a></li><li><a class="nounderline abstract_t">Hayday AC. [gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 2000; 18:975.</a></li><li><a class="nounderline abstract_t">Nikolich-Zugich J, Slifka MK, Messaoudi I. The many important facets of T-cell repertoire diversity. Nat Rev Immunol 2004; 4:123.</a></li><li><a class="nounderline abstract_t">von Boehmer H, Aifantis I, Azogui O, et al. The impact of pre-T-cell receptor signals on gene expression in developing T cells. Cold Spring Harb Symp Quant Biol 1999; 64:283.</a></li><li><a class="nounderline abstract_t">Palmer E. Negative selection--clearing out the bad apples from the T-cell repertoire. Nat Rev Immunol 2003; 3:383.</a></li><li><a class="nounderline abstract_t">Ye P, Kirschner DE. Measuring emigration of human thymocytes by T-cell receptor excision circles. Crit Rev Immunol 2002; 22:483.</a></li><li><a class="nounderline abstract_t">van den Dool C, de Boer RJ. The effects of age, thymectomy, and HIV Infection on alpha and beta TCR excision circles in naive T cells. J Immunol 2006; 177:4391.</a></li><li><a class="nounderline abstract_t">Puck JM. Laboratory technology for population-based screening for severe combined immunodeficiency in neonates: the winner is T-cell receptor excision circles. J Allergy Clin Immunol 2012; 129:607.</a></li><li><a class="nounderline abstract_t">Lewis JM, Girardi M, Roberts SJ, et al. Selection of the cutaneous intraepithelial gammadelta+ T cell repertoire by a thymic stromal determinant. Nat Immunol 2006; 7:843.</a></li><li><a class="nounderline abstract_t">Kumar BV, Connors TJ, Farber DL. Human T Cell Development, Localization, and Function throughout Life. Immunity 2018; 48:202.</a></li><li><a class="nounderline abstract_t">Prezzi C, Casciaro MA, Francavilla V, et al. Virus-specific CD8(+) T cells with type 1 or type 2 cytokine profile are related to different disease activity in chronic hepatitis C virus infection. Eur J Immunol 2001; 31:894.</a></li><li><a class="nounderline abstract_t">Tsuji-Yamada J, Nakazawa M, Minami M, Sasaki T. Increased frequency of interleukin 4 producing CD4+ and CD8+ cells in peripheral blood from patients with systemic sclerosis. J Rheumatol 2001; 28:1252.</a></li><li><a class="nounderline abstract_t">Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4:330.</a></li><li><a class="nounderline abstract_t">Kallies A, Good-Jacobson KL. Transcription Factor T-bet Orchestrates Lineage Development and Function in the Immune System. Trends Immunol 2017; 38:287.</a></li><li><a class="nounderline abstract_t">Geginat J, Paroni M, Maglie S, et al. Plasticity of human CD4 T cell subsets. Front Immunol 2014; 5:630.</a></li><li><a class="nounderline abstract_t">Cenerenti M, Saillard M, Romero P, Jandus C. The Era of Cytotoxic CD4 T Cells. Front Immunol 2022; 13:867189.</a></li><li><a class="nounderline abstract_t">Albert MH, Anasetti C, Yu XZ. T regulatory cells as an immunotherapy for transplantation. Expert Opin Biol Ther 2006; 6:315.</a></li><li><a class="nounderline abstract_t">Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol 2011; 29:621.</a></li><li><a class="nounderline abstract_t">Fasnacht N, Huang HY, Koch U, et al. Specific fibroblastic niches in secondary lymphoid organs orchestrate distinct Notch-regulated immune responses. J Exp Med 2014; 211:2265.</a></li><li><a class="nounderline abstract_t">Purwar R, Schlapbach C, Xiao S, et al. Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med 2012; 18:1248.</a></li><li><a class="nounderline abstract_t">Lu Y, Wang Q, Xue G, et al. Th9 Cells Represent a Unique Subset of CD4+ T Cells Endowed with the Ability to Eradicate Advanced Tumors. Cancer Cell 2018; 33:1048.</a></li><li><a class="nounderline abstract_t">Weaver CT, Harrington LE, Mangan PR, et al. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006; 24:677.</a></li><li><a class="nounderline abstract_t">Furuzawa-Carballeda J, Vargas-Rojas MI, Cabral AR. Autoimmune inflammation from the Th17 perspective. Autoimmun Rev 2007; 6:169.</a></li><li><a class="nounderline abstract_t">de Latour RP, Visconte V, Takaku T, et al. Th17 immune responses contribute to the pathophysiology of aplastic anemia. Blood 2010; 116:4175.</a></li><li><a class="nounderline abstract_t">Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007; 8:942.</a></li><li><a class="nounderline abstract_t">Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8:950.</a></li><li><a class="nounderline abstract_t">Oboki K, Ohno T, Saito H, Nakae S. Th17 and allergy. Allergol Int 2008; 57:121.</a></li><li><a class="nounderline abstract_t">Amin K, Lúdvíksdóttir D, Janson C, et al. Inflammation and structural changes in the airways of patients with atopic and nonatopic asthma. BHR Group. Am J Respir Crit Care Med 2000; 162:2295.</a></li><li><a class="nounderline abstract_t">McDonald DR. TH17 deficiency in human disease. J Allergy Clin Immunol 2012; 129:1429.</a></li><li><a class="nounderline abstract_t">Perniola R, Lobreglio G, Rosatelli MC, et al. Immunophenotypic characterisation of peripheral blood lymphocytes in autoimmune polyglandular syndrome type 1: clinical study and review of the literature. J Pediatr Endocrinol Metab 2005; 18:155.</a></li><li><a class="nounderline abstract_t">Kumar BV, Ma W, Miron M, et al. Human Tissue-Resident Memory T Cells Are Defined by Core Transcriptional and Functional Signatures in Lymphoid and Mucosal Sites. Cell Rep 2017; 20:2921.</a></li></ol></div><div id="topicVersionRevision">Topic 13933 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35653592" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35732829" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29752062" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Single-Cell RNA Sequencing of Lymph Node Stromal Cells Reveals Niche-Associated Heterogeneity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29727679" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Blood Development: Hematopoietic Stem Cell Dependence and Independence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23273845" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20966214" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Fate mapping analysis reveals that adult microglia derive from primitive macrophages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20154733" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Haematopoietic stem cells derive directly from aortic endothelium during development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20154732" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Blood stem cells emerge from aortic endothelium by a novel type of cell transition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25915127" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Human definitive haemogenic endothelium and arterial vascular endothelium represent distinct lineages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24471430" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Transcriptional control of early T and B cell developmental choices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18371352" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Long-term propagation of distinct hematopoietic differentiation programs in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22385655" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Hematopoietic stem cell subtypes expand differentially during development and display distinct lymphopoietic programs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8543844" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : B cells are generated throughout life in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18725575" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : B lymphocytes: how they develop and function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9834053" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : CD19+ pro-B cells can give rise to dendritic cells in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17318232" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Fetal B-cell lymphopoiesis and the emergence of B-1-cell potential.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9841928" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12040177" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : B cell antigen receptor signaling: roles in cell development and disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7524521" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The CD19/CD21 signal transduction complex of B lymphocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1373971" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Isolation and molecular characterization of the human CD34 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8166770" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The surrogate light chain in B-cell development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14500626" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cutting edge: signaling and cell surface expression of a mu H chain in the absence of lambda 5: a paradigm revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8890099" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Mutations in the mu heavy-chain gene in patients with agammaglobulinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9419212" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Mutations in the human lambda5/14.1 gene result in B cell deficiency and agammaglobulinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10525050" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Mutations in Igalpha (CD79a) result in a complete block in B-cell development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17709424" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Mutations of the Igbeta gene cause agammaglobulinemia in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8380905" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10583958" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : An essential role for BLNK in human B cell development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12705855" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Unexpected requirement for ZAP-70 in pre-B cell development and allelic exclusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6982414" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Induction of differentiation in a case of common acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6980230" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Induction of human B cell antigens in non-T cell acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2968607" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Molecular cloning of the common acute lymphoblastic leukemia antigen (CALLA) identifies a type II integral membrane protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2521388" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Common acute lymphoblastic leukemia antigen (CALLA) is active neutral endopeptidase 24.11 ("enkephalinase"): direct evidence by cDNA transfection analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7524522" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : CD20: a regulator of cell-cycle progression of B lymphocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15564720" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The biology of CD20 and its potential as a target for mAb therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2188667" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : VLA proteins in the integrin family: structures, functions, and their role on leukocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1715889" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Vascular cell adhesion molecule-1 and the integrin VLA-4 mediate adhesion of human B cell precursors to cultured bone marrow adherent cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7524518" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The role of CD40 in the regulation of humoral and cell-mediated immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1374165" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Molecular and biological characterization of a murine ligand for CD40.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15364057" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Molecular interactions regulate BCR signal inhibition by CD22 and CD72.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22566803" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : PID comes full circle: applications of V(D)J recombination excision circles in research, diagnostics and newborn screening of primary immunodeficiency disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19855403" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The follicular versus marginal zone B lymphocyte cell fate decision.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23348416" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14114163" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : THE ROUTE OF RE-CIRCULATION OF LYMPHOCYTES IN THE RAT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6866086" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A cell-surface molecule involved in organ-specific homing of lymphocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2466576" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A human lymphocyte homing receptor, the hermes antigen, is related to cartilage proteoglycan core and link proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2403843" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Expression of CD44 confers a new adhesive phenotype on transfected cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2466575" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2647304" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Adhesion molecules controlling lymphocyte migration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1688580" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Expression of the human leukocyte adhesion molecule, LAM1. Identity with the TQ1 and Leu-8 differentiation antigens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1709244" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Regulation of leukocyte adhesion molecule-1 (TQ1, Leu-8) expression and shedding by normal and malignant cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2646713" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Mouse lymph node homing receptor cDNA clone encodes a glycoprotein revealing tandem interaction domains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1974032" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Adhesion receptors of the immune system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12393420" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Temporal gene expression profile of human precursor B leukemia cells induced by adhesion receptor: identification of pathways regulating B-cell survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20038800" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : CD20 deficiency in humans results in impaired T cell-independent antibody responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18198345" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Flow cytometric immunophenotyping for hematologic neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10605604" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The role of complement in B cell activation and tolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1697696" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Adhesion of human B cells to germinal centers in vitro involves VLA-4 and INCAM-110.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10727470" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Identification of a human follicular dendritic cell molecule that stimulates germinal center B cell growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30842656" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : S-Geranylgeranyl-L-glutathione is a ligand for human B cell-confinement receptor P2RY8.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14617752" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1711157" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The B-cell surface protein CD72/Lyb-2 is the ligand for CD5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8943203" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : CD5-mediated negative regulation of antigen receptor-induced growth signals in B-1 B cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10379049" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : CD5 expression in human B-cell populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9420615" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Preferential localization of human CD5+ B cells in the peritoneal cavity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3871452" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Human B cell development. II. Subpopulations in the human fetus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1627249" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Developmental and maturational changes in human blood lymphocyte subpopulations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2154032" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The antibody repertoire of early human B cells. I. High frequency of autoreactivity and polyreactivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7533091" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Antigen-binding B cells and polyreactive antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2469441" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Probing the human B-cell repertoire with EBV: polyreactive antibodies and CD5+ B lymphocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20948548" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The importance of natural IgM: scavenger, protector and regulator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19363291" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2153188" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Clonal analysis of a human antibody response. Quantitation of precursors of antibody-producing cells and generation and characterization of monoclonal IgM, IgG, and IgA to rabies virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28248202" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Human regulatory B cells in health and disease: therapeutic potential.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20079667" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23427243" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2662716" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Structure, function, and genetics of human B cell-associated surface molecules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7945782" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : B-cell signalling via the C-type lectins CD23 and CD72.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15478378" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Rationale for new treatments aimed at IgE immunomodulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19426216" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Yin-Yang of costimulation: crucial controls of immune tolerance and function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18273020" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Two levels of protection for the B cell genome during somatic hypermutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19706817" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1760405" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : TGF-beta 1 induces germ-line transcripts of both IgA subclasses in human B lymphocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15661022" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Hyper-immunoglobulin M syndromes caused by intrinsic B-lymphocyte defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25677494" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Memory B cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2242419" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Regulation of human B-cell ontogeny.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20727034" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Plasma cell development and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17965637" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : BLIMP1 guides the fate of effector B and T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19407814" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : XBP-1 regulates signal transduction, transcription factors and bone marrow colonization in B cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15101683" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Structure and enzymology of ADP-ribosyl cyclases: conserved enzymes that produce multiple calcium mobilizing metabolites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15101683" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Structure and enzymology of ADP-ribosyl cyclases: conserved enzymes that produce multiple calcium mobilizing metabolites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8044459" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Immunological memory: a function of antigen persistence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17898316" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : The EUROclass trial: defining subgroups in common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20006554" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Lymphocyte characteristics in children with common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25918341" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Specific bone cells produce DLL4 to generate thymus-seeding progenitors from bone marrow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10837068" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23432802" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Fetal regulatory T cells and peripheral immune tolerance in utero: implications for development and disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26901814" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Neonatal thymectomy reveals differentiation and plasticity within human naive T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17935071" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Correlation between recent thymic emigrants and CD31+ (PECAM-1) CD4+ T cells in normal individuals during aging and in lymphopenic children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10946254" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : CD7 delivers a pro-apoptotic signal during galectin-1-induced T cell death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8547630" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : CD34: structure, biology, and clinical utility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10459506" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Molecular biological ontogenesis of the thymic reticulo-epithelial cell network during the organization of the cellular microenvironment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9629262" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Thymic endocrinology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16791197" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Clonal analysis reveals a common progenitor for thymic cortical and medullary epithelium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16791198" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Formation of a functional thymus initiated by a postnatal epithelial progenitor cell.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29466756" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Lineage-Determining Transcription Factor TCF-1 Initiates the Epigenetic Identity of T Cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20152168" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Notch signaling in the immune system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14688303" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Cutting edge: IL-7-dependent homeostatic proliferation of CD8+ T cells in neonatal mice allows the generation of long-lived natural memory T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10899029" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Mutations in the gene for the IL-7 receptor result in T(-)B(+)NK(+) severe combined immunodeficiency disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19935803" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Antigen presentation in the thymus for positive selection and central tolerance induction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9638477" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Thymopentin and splenopentin as immunomodulators. Current status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9950750" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Cell-fate decisions in early T cell development: regulation by cytokine receptors and the pre-TCR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11085178" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Microenvironmental regulation of T cell development in the thymus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11256748" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : CD1 proteins: targets of T cell recognition in innate and adaptive immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11402070" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : CD44 is a major E-selectin ligand on human hematopoietic progenitor cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11356007" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Signaling domains of the interleukin 2 receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14602880" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Effect of CD3delta deficiency on maturation of alpha/beta and gamma/delta T-cell lineages in severe combined immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9572735" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Thymocyte development in the absence of pre-T cell receptor extracellular immunoglobulin domains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23893766" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Regulation of cellular processes by interleukin-16 in homeostasis and cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10837080" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : [gamma][delta]cells: a right time and a right place for a conserved third way of protection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15040585" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : The many important facets of T-cell repertoire diversity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11232298" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : The impact of pre-T-cell receptor signals on gene expression in developing T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12766760" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Negative selection--clearing out the bad apples from the T-cell repertoire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12803323" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Measuring emigration of human thymocytes by T-cell receptor excision circles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16982874" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : The effects of age, thymectomy, and HIV Infection on alpha and beta TCR excision circles in naive T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22285280" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Laboratory technology for population-based screening for severe combined immunodeficiency in neonates: the winner is T-cell receptor excision circles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16829962" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Selection of the cutaneous intraepithelial gammadelta+ T cell repertoire by a thymic stromal determinant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29466753" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Human T Cell Development, Localization, and Function throughout Life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11241295" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Virus-specific CD8(+) T cells with type 1 or type 2 cytokine profile are related to different disease activity in chronic hepatitis C virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11409116" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Increased frequency of interleukin 4 producing CD4+ and CD8+ cells in peripheral blood from patients with systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12612578" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28279590" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Transcription Factor T-bet Orchestrates Lineage Development and Function in the Immune System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25566245" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Plasticity of human CD4 T cell subsets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35572552" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : The Era of Cytotoxic CD4 T Cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16548760" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : T regulatory cells as an immunotherapy for transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21314428" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Follicular helper CD4 T cells (TFH).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25311507" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Specific fibroblastic niches in secondary lymphoid organs orchestrate distinct Notch-regulated immune responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22772464" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29894691" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Th9 Cells Represent a Unique Subset of CD4+ T Cells Endowed with the Ability to Eradicate Advanced Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16782025" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Th17: an effector CD4 T cell lineage with regulatory T cell ties.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17289553" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Autoimmune inflammation from the Th17 perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20733158" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Th17 immune responses contribute to the pathophysiology of aplastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17676045" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17676044" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Development, cytokine profile and function of human interleukin 17-producing helper T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18427165" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Th17 and allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11112154" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Inflammation and structural changes in the airways of patients with atopic and nonatopic asthma. BHR Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22554706" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : TH17 deficiency in human disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15751604" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Immunophenotypic characterisation of peripheral blood lymphocytes in autoimmune polyglandular syndrome type 1: clinical study and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28930685" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Human Tissue-Resident Memory T Cells Are Defined by Core Transcriptional and Functional Signatures in Lymphoid and Mucosal Sites.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
